

**UCC Library and UCC researchers have made this item openly available.
Please [let us know](#) how this has helped you. Thanks!**

Title	Lack of acute or chronic effects of epicatechin-rich and procyanidin-rich apple extracts on blood pressure and cardiometabolic biomarkers in adults with moderately elevated blood pressure: a randomized, placebo-controlled crossover trial
Author(s)	Hollands, Wendy J.; Tapp, Henri; Defernez, Marianne; Perez Moral, Natalia; Winterbone, Mark S.; Philo, Mark; Lucey, Alice J.; Kiely, Mairead E.; Kroon, Paul A.
Publication date	2018-11-23
Original citation	Hollands, W. J., Tapp, H., Defernez, M., Perez Moral, N., Winterbone, M. S., Philo, M., Lucey, A. J., Kiely, M. E. and Kroon, P. A. (2018) 'Lack of acute or chronic effects of epicatechin-rich and procyanidin-rich apple extracts on blood pressure and cardiometabolic biomarkers in adults with moderately elevated blood pressure: a randomized, placebo-controlled crossover trial', American Journal of Clinical Nutrition, 108(5), pp. 1006-1014. doi:10.1093/ajcn/nqy139
Type of publication	Article (peer-reviewed)
Link to publisher's version	www.clinicaltrials.gov as NCT02013856. http://dx.doi.org/10.1093/ajcn/nqy139 Access to the full text of the published version may require a subscription.
Rights	© 2018, American Society for Nutrition. This is a pre-copyedited, author-produced version of an article accepted for publication in American Journal of Clinical Nutrition following peer review. The version of record is available online at: https://doi.org/10.1093/ajcn/nqy139
Embargo information	Access to this article is restricted until 12 months after publication by request of the publisher.
Embargo lift date	2019-11-23
Item downloaded from	http://hdl.handle.net/10468/7229



Downloaded on 2021-11-27T05:25:28Z

UCC

University College Cork, Ireland
Coláiste na hOllscoile Corcaigh

Lack of acute or chronic effects of epicatechin-rich and procyanidin-rich apple extracts on blood pressure and cardiometabolic biomarkers in adults with moderately elevated blood pressure: a randomized, placebo-controlled, cross-over trial

Wendy J Hollands¹, Henri Tapp¹, Marianne Defernez¹ Natalia Perez Moral¹, Mark S Winterbone¹ Mark Philo¹, Alice J Lucey², Mairead E Kiely² and Paul A Kroon¹

¹Quadram Institute 45Bioscience, Norwich Research Park, Norwich NR4 7UA, UK.

²Cork Centre for Vitamin D and Nutrition Research, School of Food and Nutritional Sciences, University College Cork, Cork, Ireland.

Author names for pubmed indexing: Hollands, Tapp, Defernez, Perez Moral, Winterbone, Philo, Lucey, Kiely, Kroon.

Corresponding author: Dr Paul Kroon, Quadram Institute Bioscience, Norwich Research Park, Colney Lane, Norwich, NR4 7UA, UK.

E-mail: paul.kroon@quadram.ac.uk

Tel: + 44 (0) 1603 255236

Abbreviations

AI, Augmentation Index; ba_PWV, brachial-ankle pulse wave velocity; cf_PWV, carotid femoral pulse wave velocity; DPB, diastolic blood pressure; EC,

epicatechin (refers to (-)-EC unless stated otherwise); ET-1, endothelin-1; FMD, flow-mediated dilatation; NO, nitric oxide; PC, procyanidin; SBP, systolic blood pressure; TAG, triglycerides.

Clinical trials.gov (Ref no: NCT02013856)

Funding source: This research received funding from the European Community's Seventh Framework Programme (FP7 under agreement no. 312090, project BACCHUS) and by the Biotechnology and Biological Sciences Research Council (UK) through and Institute Strategic Programme Grant ('Food and Health; Grant No: BB/J004545/1) to the Quadram Institute Bioscience (previously the Institute of Food Research).

1 **ABSTRACT**

2 **Background:** The reported effects of flavanol-rich foods such as cocoa, dark
3 chocolate and apples on blood pressure and endothelial function may be due
4 to the monomeric flavanols (mainly (-)-epicatechin (EC)), the oligomeric
5 flavanols (procyanidins; PC) or other components. Reports of well controlled
6 intervention studies that test the effects of isolated oligomeric flavanols on
7 biomarkers of cardiovascular health are lacking.

8 **Objective:** We studied the acute and chronic effects of an EC-rich apple
9 flavanol extract and isolated apple PCs on systolic BP and other
10 cardiometabolic biomarkers.

11 **Design:** Forty-two healthy men and women with moderately elevated BP
12 completed this randomized double-blind, placebo-controlled, four arm
13 crossover trial. Participants ingested a single dose of an apple flavanol extract
14 (70 mg monomeric flavanols, 65 mg PC), a double dose of this extract (140
15 mg monomeric flavanols, 130 mg PC), an apple PC extract (130 mg PC, 6.5
16 mg monomeric flavanols) or placebo capsules once daily for 4 weeks, in
17 random order. Biomarkers of CVD risk and vascular function were measured
18 before and 2h after ingestion of the first dose, and after 4 weeks intervention.

19 **Results:** Compared to the placebo, none of the isolated flavanol treatments
20 significantly ($p < 0.05$) changed SBP or DBP (peripheral and aortic), plasma
21 NO reaction products or measures of arterial stiffness (cf_PWV, ba_PWV and
22 AI) after 2 h or 4 weeks of intervention. There were no changes in plasma
23 endogenous metabolite profiles, or circulating NO, endothelin-1, total-, HDL-,
24 LDL-cholesterol, TAGs, fasting glucose, fructosamine and insulin after 4
25 weeks of intervention.

26 **Conclusions:** Our data suggest that in isolation, neither monomeric flavanols
27 or PC affect BP, blood lipid profiles, endothelial function or glucose control in
28 individuals with moderately elevated blood pressure. The reported benefits of
29 consuming flavanol-rich cocoa, chocolate and apple products appears to be
30 dependent on other components, which may work in combination with
31 monomeric flavanols/PC.

32 INTRODUCTION

33 Monomeric flavanols such as epicatechin (EC) and their oligomeric derivatives
34 (procyanidins; PC) are a sub-class of the flavonoids that are widely available as part of
35 the human diet. Some epidemiological studies have reported an inverse correlation
36 between the consumption of flavanol-rich foods and cardiovascular disease (CVD) (1-
37 3). These observations are substantiated by several meta-analyses of human
38 intervention trials demonstrating that acute and chronic ingestion of flavanol-rich foods
39 and beverages such as dark chocolate, cocoa products and apples causes decreases
40 in blood pressure (BP) in both healthy, normotensive individuals and hypertensive
41 patients (4-6), reductions in serum insulin (7) and improvements in circulating lipid
42 profiles (4, 8). Similarly, some studies have demonstrated significant reductions in
43 fasting blood glucose (9) as well as improvements in markers of vascular function
44 such as endothelial-derived nitric oxide (NO) (10-12), endothelin-1 (ET-1) (10) and
45 pulse wave velocity (PWV) (13, 14), a measure of arterial stiffness and an emerging
46 marker of CVD risk.

47 The main food sources studied for their BP-lowering properties are flavanol-rich
48 cocoa products, tea and apples. Meta-analyses of randomized controlled trials (RCTs)
49 reported that repeated daily ingestion of chocolate and cocoa beverages over 2-18
50 weeks significantly reduced systolic BP (SBP) and diastolic BP (DBP) by 5.9 mmHg
51 and 3.3 mmHg (4) and by 4.5 and 2.5 mmHg (6).

52 Evidence as to whether or not the cardio-protective effects observed in
53 intervention studies with cocoa/chocolate and other flavanol-rich foods/extracts are
54 due to the EC monomer is inconsistent (12, 15-17). For example, Schroeter et al.
55 published data from human dietary intervention studies and mouse aortic ring
56 relaxations experiments with cocoa flavanols and isolated EC and concluded that EC

57 was responsible for the beneficial effects of cocoa flavanols on endothelial function
58 (12), whereas other studies have reported no significant effects of a similar dose of
59 isolated EC on endothelial function in humans (20). Even though PC have been
60 shown to possess potent biological activity in vitro (17, 18), we are not aware of any
61 studies that have assessed the effects of isolated PC (i.e. depleted of flavanol
62 monomers) on blood pressure in humans.

63 The aim of this study was to investigate the effects of isolated flavanols on BP
64 and other biomarkers of cardiometabolic health. To achieve this, we used (i) an EC-
65 rich flavanol extract derived from flavanol-rich apples for which we have previously
66 reported the bioavailability of EC and shown it to be similar to that for cocoa products
67 (19), and (ii) an apple PC extract that was depleted of monomeric flavanols. The apple
68 flavanol extracts are devoid of other bioactive substances found in cocoa extracts
69 such as the methylxanthines. We report the effects of the EC-rich flavanol extract at
70 two doses and the effects of a PC rich extract depleted of monomeric flavanols versus
71 a placebo control. To assess the broader effects of flavanols on host metabolism, we
72 also report, to our knowledge for the first time, the effects of the treatments on plasma
73 metabolite profiles using a non-targeted LC-MS based platform that allows relative
74 quantification of several hundred metabolites, the majority being host metabolites.

75

76 **SUBJECTS AND METHODS**

77

78 **Study population**

79 Forty-three, apparently healthy men and women aged 50+ years with a SBP
80 between 120 and 159 mmHg at eligibility assessment were recruited in and around
81 Norwich, UK. Office SBP was measured by a research nurse using an automated BP

82 monitor (Omron). The exclusion criteria were as follows: smoking; medical
83 conditions such as gastrointestinal disease, diabetes, cancer, heart disease, stroke;
84 HRT (unless stable on therapy for a period of at least 6 months); medications judged
85 to affect the trial outcome such as blood pressure and lipid lowering therapy; some
86 dietary supplements (e.g. fish oils); clinical results at eligibility assessment judged to
87 affect the trial outcome or be indicative of a health problem. The study period was
88 from August 2014 to March 2016. The trial was conducted in the Human Nutrition
89 Unit at the Quadram Institute Bioscience, Norwich, UK (formerly Institute of Food
90 Research) and all procedures were approved by both the Human Research
91 Governance Committee of the Quadram Institute Bioscience and the Norfolk
92 Research Ethics Committee. Each participant gave written informed consent prior to
93 taking part in the trial. The trial is registered with clinicaltrials.gov (Ref:
94 NCT02013856).

95

96 **Study design**

97 The study was a randomized, double-blind, placebo-controlled four arm crossover
98 trial investigating the acute and chronic effects of apple derived flavanols on risk
99 markers for CVD (**Figure 1**). The four treatments were: (i) an apple extract delivering
100 70 mg monomeric flavanols and 65 mg PC (low dose), (ii) an apple extract delivering
101 140 mg monomeric flavanols and 130 mg PC (high dose), (iii) an apple extract
102 depleted of monomeric flavanols but containing 130 mg PC, and (iv) a placebo
103 control. Apple extracts and placebo (microcrystalline cellulose) were delivered in
104 opaque, cellulose based capsules suitable for oral consumption and which release
105 their contents within 15 minutes of reaching the stomach (K-caps vegetarian
106 capsules; GoCap).

107 The primary outcome measure for this trial was SBP. Secondary outcome
108 measures were biomarkers of endothelial function and cardiometabolic risk including
109 blood lipids (total cholesterol, HDL/LDL cholesterol and TAG), glucose, insulin,
110 fructosamine, ET-1, plasma NO reaction products, and measures of arterial stiffness
111 (cf_PWV, ba_PWV and AI).

112 The apple extracts and placebo were encapsulated and bottled before the start
113 of the trial, with all capsules having identical appearance. The encapsulated
114 flavanols were shown to remain stable throughout the study by regular analysis of
115 sample capsule contents for monomeric and oligomeric flavanols using a validated
116 method (20). The four treatments were randomly allocated as A, B, C or D by a
117 designated person not assigned to the trial. The order in which the participants
118 ingested the treatments was determined by a computer generated
119 (randomization.com) sequence of letters from A-D using a block randomisation
120 approach. Participants meeting the eligibility criteria were allocated sequentially to a
121 treatment sequence upon enrolment by the study manager. The participants,
122 principal investigator, study manager, nurse, statistician and those assessing
123 outcomes were blinded to the interventions; un-blinding was done once statistical
124 analyses were complete.

125 Capsules (n=2) were ingested once daily (in the morning) for 28 d with a
126 minimum two-week washout period between each of the treatments. To aid
127 compliance, participants were provided with a capsule checklist and asked to record
128 consumption of the capsules on each day. Compliance to treatment was assessed
129 from the checklist and by counting the unused capsules returned at the end of the
130 treatment period. For 24 h prior to the start of each treatment period and for the 28 d
131 treatment period, participants were asked to exclude from their diets some food

132 sources that contribute significantly to total flavanol intake (e.g. dark
133 chocolate/cocoa) and limit other food sources to levels that would support
134 compliance (i.e. tea, berry fruits) or have known cardio-protective effects (e.g. oily
135 fish). Foods on the limited list were completely excluded from the diet for 24 h prior
136 to assessment days. A list of prohibited and limited foods was provided to the
137 participants to aid compliance.

138 Participants were assessed at the start and end of each 28 d treatment period.
139 To investigate the chronic effects of flavanols on risk markers for CVD the following
140 measurements were made on day 1 at 0 h (baseline) and day 29 of each treatment
141 period: blood pressure (peripheral and aortic); arterial stiffness (ba_PWV; cf_PWV;
142 AI); fasting blood samples were collected for the analysis of plasma flavanols;
143 circulating levels of lipids/lipoproteins, glucose, fructosamine, insulin, NO reaction
144 products and ET-1. To investigate the acute effects of flavanols on risk markers for
145 CVD, BP, arterial stiffness and NO reaction products were re-assessed 2 h after
146 ingestion of the capsules on day 1. This time point was chosen to coincide with
147 expected peak plasma concentrations of flavanols and participants remained fasted
148 until completion of the 2-h measurements.

149

150 **Apple extracts**

151 The apple extracts were produced from a crude apple juice by a combination of
152 alcoholic extraction and chromatographic separation to generate i) an epicatechin-
153 rich extract containing around 30 % (w/w) of monomeric catechins (90% (-)-EC, 10%
154 (+)-catechin) that retained some of the PC and ii) an oligomeric PC rich extract that
155 was significantly depleted of monomeric catechins. Both materials were produced
156 from the same single crop of apples grown in Herefordshire, UK. Extracts were

157 analysed for monomeric and oligomeric catechins by HPLC-based separation using
158 a HILIC stationary phase (Luna Hilic column 150 x 2.0 mm; 3 μ M) coupled with
159 fluorescence detection as described previously (20). The flavanol composition of the
160 three apple treatments is shown in **Table 1**. In addition, the apple extracts were
161 shown to contain only the (-)-enantiomer of EC and the (+)-enantiomer of catechin
162 using an HPLC column with a chiral stationary phase. The extracts contained minor
163 quantities of other apple polyphenols as follows: Epicatechin-rich extract (low dose) -
164 4.5 mg chlorogenic acid, 3.2 mg phloridzin, <1 mg quercetin glycosides; procyanidin-
165 rich extract – 11.8 mg chlorogenic acid, 10.3 mg phloridzin, 3.0 mg quercetin
166 glycosides.

167

168 **Blood pressure assessment**

169 Office BP was measured using an automated BP monitor (Omron M6).

170 Measurements were conducted in a quiet room after a 10 min period of rest with the
171 participant in a semi-supine position and the arm resting at heart level.

172 Measurements were conducted using the same designated arm (determined at
173 eligibility assessment) for the duration of the entire study. Four consecutive readings
174 were obtained at 5 min intervals, and the first reading discarded.

175 BP was also assessed using the validated Vicorder device (Smart Medical;
176 Gloucester, UK). Peripheral SBP (pSBP) and peripheral DBP (pDBP) measurements
177 were obtained in a similar manner to office BP. Aortic SBP (aSBP) and aortic DBP
178 (aDBP) were derived from the peripheral BP and brachial pulse wave analysis from
179 an in-built transfer function of the vicorder device. To minimize the effects of diurnal
180 variation in BP, baseline and day 29 measurements were always conducted at the
181 same time of day (07.30 – 08.00) for all participants.

182

183 Arterial stiffness assessments

184 Cf_PWV, ba_PWV and AI were measured with participants in the semi-supine
185 position (30° angle) using the vicorder device. To determine cf_PWV, an inflatable
186 sensor (30 mm) was placed over the right carotid region and a BP cuff placed
187 around the upper right thigh to measure the carotid and femoral pressure pulse
188 waves, respectively. Path length was determined by measuring the distance (in cm)
189 between the supra-sternal notch and the mid-point of the thigh cuff. The carotid
190 sensor and thigh cuff were inflated (~ 60 mmHg) and waveforms simultaneously
191 recorded over 10-15 consecutive heartbeats. To determine ba_PWV, BP cuffs were
192 placed around the ankle and the right upper arm. Path length was determined by
193 measuring the distance between the supra-sternal notch and the mid-point of the
194 ankle cuff. Both cuffs were inflated and pressure waveforms simultaneously
195 recorded.

196

197 Biochemical markers for CVD

198 Whole blood was collected into EDTA, heparin and serum separating tubes (Becton-
199 Dickenson). Samples collected into EDTA and heparin tubes were immediately
200 centrifuged at 2500 x g for 10 mins. Samples collected in serum separating tubes
201 were centrifuged after 30 minutes at 2000 x g for 10 mins. After centrifugation,
202 plasma and serum were stored at -80 °C until analysis.

203

204 Plasma ET-1 and insulin status were determined using commercially available
205 ELISA kits (R&D systems) according to the manufacturer's instructions. Serum lipids
206 (total/HDL/LDL cholesterol and TAG), glucose and fructosamine status were

207 determined using an automated clinical chemistry analyser (Randox; Daytona plus).
208 The plasma concentration of NO reaction products (nitrate + nitrite + nitrosothiols)
209 was determined using a Sievers 280i NO analyser (Sievers Instruments Inc)
210 comprising of a purge vessel attachment, hot water bath to control the temperature
211 of the reaction vessel and a chill bath to control the condenser. The 280i NOA
212 reduces nitrite, nitrate and nitrosothiols to NO in the purge vessel which is then
213 quantified according to the chemiluminescence signal released transiently within the
214 instrument. Plasma samples were deproteinated with cold ethanol (1:2 dilutions) and
215 centrifuged before analysis. Samples (20 μ L) were injected onto the purge vessel
216 and analysed in triplicate.

217

218 **Plasma metabolite profiles**

219 Identification of the plasma metabolites in d1 (baseline) and d29 samples was
220 conducted by Metabolon USA (www.metabolon.com) using ultra-performance liquid
221 chromatography (Waters ACQUITY)) and a high resolution mass spectrometer
222 (Thermo Scientific) interfaced with a heated electrospray ionization source and
223 orbitrap mass analyser operated at 35,000 mass resolution. A total of 671 relevant
224 metabolites were identified. The classes of metabolites were: xenobiotics, lipids
225 amino acids, nucleotides, peptides, carbohydrates, vitamins and catecholamines
226 (**see on-line supplemental Table 3 for a list of all metabolites**). Values were
227 normalized in terms of raw area counts, each metabolite rescaled to set the median
228 equal to 1, and any missing values imputed with the minimum observed value for
229 each compound. The average percentage missing values was 10.2% overall; 32.1%
230 for xenobiotics, 5.9% for non-xenobiotics, and 4.5% for the dataset used for
231 multivariate analyses (see below).

232

233 Analysis of epicatechin in plasma

234 Plasma samples (200 μ l) were mixed with 5 % aqueous trichloroacetic acid (200 μ l)
235 and dimethylformamide (200 μ l). Taxifolin (10 μ l; 10 μ g/mL) was added as an internal
236 standard. Samples were vortexed mixed before centrifugation at 17,000 g for 15
237 min. Post centrifugation, samples were filtered (0.45 μ m disposable filter) prior to
238 UPLC-MS analysis.

239 Samples were injected onto a Waters C18 column (100 mm \times 2.1 mm; 1.7
240 μ M) connected to an Agilent 1200 LC system with the eluent passing through a
241 diode array detector and a triple quadrupole mass spectrometer (Applied Biosystems
242 6490, Ontario, Canada) and eluted at a flow rate of 0.4 ml/min. Elution was achieved
243 using a gradient of increasing solvent B (acetonitrile and 0.1% acetic acid) from
244 solvent A (water and 0.1% acetic acid) as follows: T = 0 min, solvent B = 5%; t = 0.5
245 min, solvent B = 5%; t = 10 min, solvent B = 95%; t = 11 min, solvent B = 95%; t =
246 11.1 min, solvent B = 5% and t = 13 min, solvent B = 5%. The injection volume was
247 1 μ L. Catechin/EC metabolites were quantified against a (-)-EC standard over the
248 range 10 – 1000 μ g/mL.

249

250 Statistical analysis

251 The study was powered to detect a mean reduction in SBP of 4.1 mmHg at 90%
252 power and with a significance level of 0.05, and the pre-study power calculation was
253 based on SBP in a cohort of participants enrolled in a study conducted at University
254 College Cork, Ireland. The calculations supported the recruitment of 39 participants
255 in total. For the biomarkers of CVD risk, post – pre-differences between the four
256 treatments were analysed using a non-parametric repeated measures ANOVA after

257 excluding subjects with an incomplete set of differences. All data are presented as
258 means \pm SD.

259 Plasma metabolite data were analysed using multivariate methods were used to
260 analyse the plasma metabolite data. For this, Xenobiotics and compounds for which
261 more than half the values were missing (110 & 11 compounds, respectively) were
262 removed, after checking the prevalence of missing values was not treatment specific.
263 The resulting dataset (8 measurements per volunteer x 550 compounds, logged
264 data) was analysed by Principal Component Analysis (PCA) (21) and by ANOVA-
265 simultaneous component analysis (ASCA) (22) with factors time, treatment, and an
266 interaction term. For ASCA a permutation test to each factor (x1000 permutations)
267 provided a p-value (H_0 = the factor has no effect on the experimental outcome). A
268 second dataset was derived (ratio between values at day 29 and day 1, logged) and
269 analysed by PCA. One to fourteen scores were used as input for classification into 4
270 groups (high monomeric flavanol dose, low monomeric flavanol dose, placebo and
271 PC) by discriminant analysis (21). A permutation test (random attribution of each
272 volunteer's 4 measurements to 4 groups x1000 permutations) was used to generate
273 a p-value (probability of getting the classification success rate obtained with the real
274 groups if there was no structure to the data). All analyses were conducted in Matlab
275 2015a (The Mathworks, Cambridge, UK) except for ASCA which was carried out with
276 the PLS Toolbox (version 8.01; EigenVector Research) (23).

277

278 **RESULTS**

279

280 **Study population**

281 Of the forty-three participants randomized to treatment, forty two completed the trial
282 (15 men and 27 women). One participant withdrew part way through the first test
283 period citing difficulties with study time commitments as the reason for withdrawal.
284 No serious adverse events were reported during the trial. **Figure 1** shows the flow of
285 participants through the trial. Participant parameters at eligibility assessment were
286 (mean \pm SD, n=42): age 63 ± 7 years; BMI 25.9 ± 3.1 kg/m²; SBP 137 ± 10 ; DBP 80
287 ± 7 mmHg. Compliance to treatments was high with overall compliance of 99.7%
288 (capsules taken as a proportion of intended total) and individual compliance of \geq
289 92%.

290

291 **Absorption of epicatechin and metabolites**

292 Plasma EC metabolites were not detected in the baseline samples collected prior to
293 the start of any of the treatments. Mean plasma total EC metabolite concentrations
294 2 h after ingestion of the low and high dose EC treatments were 3.51 ± 2.2 and 9.07
295 ± 4.71 , $\mu\text{mol/L}$, respectively. The major metabolites were EC-monoglucuronides, EC-
296 monosulfates and methyl-EC-monosulfates. As expected, only trace amounts of EC
297 metabolites were detected 2 h after ingestion of the PC treatment (mean plasma
298 peak concentration, $0.01 \mu\text{mol/L}$). EC metabolites were not detected in any of the
299 samples collected after ingestion of the placebo treatment, demonstrating excellent
300 adherence to the low flavanol diet by all participants.

301

302 **Effects of treatments on SBP and other markers of CVD risk**

303 **Table 2** shows the mean values for the various biomarkers of CVD risk for all
304 participants at the start of the trial. All values were within reported physiological
305 ranges. At 2 h after the ingestion of different doses of apple flavanols, no significant

306 differences were observed in SBP, DBP (peripheral and aortic), plasma NO,
307 cf_PWV, ba_PWV or AI between treatments and placebo control (**Table 3**).
308 Furthermore, we did not observe significant differences in BP, arterial stiffness or the
309 plasma biomarkers ET-1, NO reaction products, total cholesterol, HDL/LDL
310 cholesterol, triglycerides, glucose, fructosamine or insulin after 4 weeks' intervention
311 (**Table 4**). Post-hoc analysis of the primary outcome data (sBP; SD of differences =
312 5.69 mm Hg) showed that the study had a power of 80% to detect a difference of
313 2.53 mm Hg ($P < 0.05$) between placebo and any one of the other treatments.

314

315 **Effects of treatments on metabolic profiles**

316 Inter-individual differences in metabolite profiles were large relative to differences
317 between profiles of a given individual measured for different treatments and time
318 points (see PCA scores plot of individual metabolite profiles, **Figure 2 A and**
319 **supplemental Figure 1 A**). The change in profiles between the two time-points
320 was, however, of a similar scale between individuals (see PCA scores plot for ratioed
321 data, (d29 vs d1), **Figure 2 B and supplemental Figure 1 B**). However, the overall
322 success rate of classification of the profiles into the four treatment groups was no
323 higher than would be expected by chance ($p > 0.1$). Moreover, in the multivariate
324 analysis of variance ASCA neither time, treatment, or their interaction, was found to
325 be significant ($p = 0.91$, $p = 1$, $p = 1$ respectively). This suggested that none of the
326 treatments altered the metabolite profiles in a statistically significant (i.e. consistent)
327 way.

328

329 **DISCUSSION**

330 The main finding of this study was that, compared to a placebo control, there were
331 no significant effects of consuming an EC-rich flavanol extract (at doses of 70 or 140
332 mg monomeric flavanols/d) or a monomeric flavanol-depleted PC-rich extract either
333 2 h after a single dose (acute) or after daily consumption for 28 days on SBP or any
334 of the other biomarkers of cardiometabolic risk. The appearance of EC phase-2
335 conjugates in plasma 2 h after ingestion of the EC-rich flavanol extracts
336 demonstrates that the EC was effectively absorbed resulting in mean peak plasma
337 concentrations in the 3-10 $\mu\text{mol/L}$ range, which is in keeping with previous reports
338 (19). Since the isolated PC treatment provided a dose of procyanidin equivalent to
339 that for the high dose EC-rich flavanol extract, these data show that neither
340 monomeric flavanols nor PC significantly affected any of the cardiometabolic
341 biomarkers. Further, they confirm the findings of a previously published report which
342 indicated that PC are not a source of monomeric flavanols (i.e. EC and catechin are
343 not released during fermentation by the gut microbiota) (24).

344 Oligomeric PC have been shown to exert biological activity in vitro (17, 18) but
345 their bioavailability is very limited, and only nM concentrations of dimers and
346 occasionally trimers have been reported to appear in peripheral blood. As far as we
347 are aware, the current report is the first RCT describing the effects of isolated PC on
348 biomarkers for CVD. The finding of no significant effects on any of the biomarkers
349 assessed is consistent with the limited bioavailability of PC, although it is possible that
350 PC can exert effects in the body via the absorption of gut microbiota-derived
351 metabolites such as hydroxyphenyl- γ -valerolactones, phenylvaleric acids and
352 hydroxyphenylacetic acids which may be more extensively absorbed (25, 26).
353 Although the data presented here do not suggest that these gut microbiota-derived
354 metabolites were effective in changing the biomarkers assessed in this study, further

355 research of their biological activities is warranted. As a group, the microbiota-derived
356 ring fission products represent the most substantial form of EC metabolites in humans,
357 accounting for 78% of the radiolabel absorbed and excreted in urine over the 48 hours
358 following ingestion of a single dose of [2-¹⁴C]-(-)-EC compared to 22% for epicatechin
359 phase-2 conjugates (26).

360 Despite the lack of clinical effects of monomeric and oligomeric flavanols in this
361 report, the BP-lowering effects of flavanol-rich foods and extracts has been reported
362 for a significant number of human intervention trials, most commonly after
363 consumption of cocoa and cocoa based products over various durations in both
364 healthy and non-healthy populations. Several meta-analyses of these trials report
365 significant mean reductions in SBP as follows; 5.9 (p = 0.0003) (4), 4.5 (p = <0.001)
366 (6), 2.8 (p = 0.005) (27) and 4.7 (p = 0.002) mmHg (5). The largest net reduction in
367 office SBP observed in our trial was 0.39 mmHg after 28 d ingestion of the apple
368 extract containing a 70 mg dose of monomeric flavanols; this falls well short of the
369 BP responses reported in meta-analyses, was not significant, and there was not an
370 increased response at the higher dose. Aside from the differences in study design
371 (e.g. hypertensive vs normotensive, dose and duration of intervention, food matrix
372 etc.) which makes direct comparisons in systematic reviews challenging, it has been
373 hypothesised that the 'open label' approach to the treatments in many of these trials
374 (e.g. flavanol-rich dark chocolate vs flavanol poor white chocolate) has increased the
375 potential for the observed reductions in BP to be an 'exaggerated' placebo effect.
376 This is supported by the lack of effect observed in several trials after ingestion of a
377 cocoa beverage, in which the control drink has been better able to facilitate a blinded
378 approach to the treatment, and that the effects of cocoa intervention trials on BP

379 were weak and non-significant when sub-grouped to take account of the blinding of
380 participants to the treatment (-0.71 mmHg, $p = 0.54$) (27).

381 Ingestion of flavanol-rich foods and beverages has also been reported to cause
382 improvements in other biomarkers of CVD risk. For example, meta-analyses of human
383 intervention trials after cocoa and green tea supplementation have shown significant
384 reductions in serum insulin (7) and LDL cholesterol (4, 28, 29). In the study reported
385 here, the largest reduction in LDL cholesterol was 0.08 mmol/L after 28 d
386 supplementation with the apple flavanol extract containing 70 mg of monomeric
387 flavanols. This effect size is 2-3-fold less than the overall reductions observed in the
388 reported meta-analyses of RCT's, and is not significant. Similarly, in some trials cocoa
389 ingestion has been shown to decrease plasma ET-1 and increase plasma NO reaction
390 products (10, 30) and in a dose dependant manner (30). We previously reported a
391 significant increase in plasma NO 6 h after ingestion of apple purees containing 25
392 and 100 mg EC but not after 14 d ingestion (31). However, the magnitude of change in
393 NO reaction products was similar for both doses of EC/flavanols, and there was not an
394 associated effect on ET-1. Likewise, 4 weeks' ingestion of a cocoa beverage
395 containing as little as 64 mg EC/d has been reported to significantly reduce cf_PWV
396 by 0.4 m/s (13) which is double the reduction of 0.2 m/s observed for the equivalent
397 duration and dose of epicatechin ingested by participants in the study reported here.

398 There is a contradiction between an increasing number of reports describing
399 increases in flow mediated dilatation, reductions in BP and changes in other
400 biomarkers caused by consumption of flavanol-rich complex foods and beverages,
401 and in particular cocoa and cocoa products, and the more recent reports that show no
402 significant effects of purified EC (19, 20, this report) and purified PC (this report) on
403 these vascular biomarkers. Two alternative paradigms can be considered: Either (i)

404 the physiological effects of consuming cocoa / dark chocolate are caused by other
405 components in cocoa and are not dependent on the flavanols or (ii) the flavanols are
406 involved in causing these effects but only in combination with other components in
407 cocoa. Cocoa contains other compounds such as sugar, fats and bioactive
408 phytochemicals including the methylxanthines theobromine and caffeine, all of which
409 have the potential to affect the physiological responses to consumption of cocoa
410 products. Theobromine for example, is present in chocolate at concentrations up to
411 1.4% by weight (32) and there is evidence that it has biological activity (33, 34), and
412 the effects of caffeine are widely reported and include increasing FMD and BP and
413 reducing insulin sensitivity (35, 36). Further, a recent report provides evidence from
414 carefully controlled dietary intervention trials to support the supposition that cocoa
415 flavanols work in combination with other cocoa components to affect BP, endothelial
416 function and other vascular biomarkers (37). Sansone and colleagues show that cocoa
417 flavanols alone significantly increased flow mediated dilatation (FMD) of the brachial
418 artery but did not significantly decrease BP 2 h after consumption of the test drinks,
419 whereas when administered in combination with methylxanthines, both FMD and DBP
420 were improved, and the FMD increase was significantly higher than with cocoa
421 flavanols alone. Methylxanthines alone did not significantly affect FMD, DBP or SBP.
422 These recent findings (lack of effects of isolated monomeric and oligomeric PC on BP
423 (15, 16) this report), and a recent report showing that cocoa flavanols were only
424 effective in reducing BP when administered in combination with methylxanthines (37)
425 serves as a reminder that foods are complex and contain numerous compounds,
426 therefore, ascribing a physiological response to consumption of a complex food like
427 cocoa to just one compound or class of compounds is somewhat naive. Although it
428 could be argued that not using a complex food such as apples or cocoa as the

429 treatment was a weakness in the trial design, the appropriate placebo food products
430 (apples and cocoa that are similar except they lack the flavanols) are not available.

431

432 **CONCLUSION**

433 Acute and chronic consumption of isolated apple monomeric flavanols and PC
434 oligomers had no significant effect on BP, various other cardiometabolic biomarkers
435 or the concentrations of circulating host metabolites in pre-hypertensive adults.
436 These data do not support the notion that in isolation, monomeric flavanols and/or
437 PC can significantly affect blood pressure and other biomarkers of cardiometabolic
438 risk.

439

440 **ACKNOWLEDGEMENTS**

441 The authors thank Dr Shikha Saha (Quadram Institute Bioscience) for assistance
442 with the chiral analysis of the apple extract. Author contributions were as follows:
443 PAK, WJH, AJL, MEK designed the study; WJH was responsible for participant
444 recruitment and day to day management of the trial; WJH and NP conducted
445 physiological study measurements; WJH, NP, MP and MW analysed biological
446 samples; HT and MD analysed data; WJH and PAK wrote the manuscript; PAK had
447 primary responsibility for final content. All authors read and approved the final
448 manuscript. The authors declare no conflicts of interest.

449

REFERENCES

1. Buijsse B, Feskens EJ, Kok FJ, Kromhout D. Cocoa intake, blood pressure, and cardiovascular mortality: the Zutphen Elderly Study. *Arch Intern Med* 2006;166(4):411-7. doi: 166/4/411 [pii] 10.1001/411.
2. Mink PJ, Scrafford CG, Barraj LM, Harnack L, Hong CP, Nettleton JA, Jacobs DR, Jr. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. *Am J Clin Nutr* 2007;85(3):895-909. doi: 85/3/895 [pii].
3. Hertog MG, Feskens EJ, Hollman PC, Katan MB, Kromhout D. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. *Lancet* 1993;342(8878):1007-11. doi: 0140-6736(93)92876-U [pii].
4. Hooper L, Kroon PA, Rimm EB, Cohn JS, Harvey I, Le Cornu KA, Ryder JJ, Hall WL, Cassidy A. Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. *Am J Clin Nutr* 2008;88(1):38-50. doi: 88/1/38 [pii].
5. Taubert D, Roesen R, Schomig E. Effect of cocoa and tea intake on blood pressure: a meta-analysis. *Archives of internal medicine* 2007;167(7):626-34. doi: 10.1001/archinte.167.7.626.
6. Desch S, Schmidt J, Kobler D, Sonnabend M, Eitel I, Sareban M, Rahimi K, Schuler G, Thiele H. Effect of cocoa products on blood pressure: systematic review and meta-analysis. *Am J Hypertens* 2010;23(1):97-103. doi: 10.1038/ajh.2009.213.
7. Hooper L, Kay C, Abdelhamid A, Kroon PA, Cohn JS, Rimm EB, Cassidy A. Effects of chocolate, cocoa, and flavan-3-ols on cardiovascular health: a systematic review and meta-analysis of randomized trials. *Am J Clin Nutr* 2012;95:740-51. doi: ajcn.111.023457 [pii] 10.3945/ajcn.111.023457.
8. Lin X, Zhang I, Li A, Manson JE, Sesso HD, Wang L, Liu S. Cocoa Flavanol Intake and Biomarkers for Cardiometabolic Health: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *J Nutr* 2016. doi: 10.3945/jn.116.237644.
9. Sarria B, Martinez-Lopez S, Sierra-Cinos JL, Garcia-Diz L, Mateos R, Bravo L. Regular consumption of a cocoa product improves the cardiometabolic profile in healthy and moderately hypercholesterolaemic adults. *Br J Nutr* 2014;111(1):122-34. doi: 10.1017/S000711451300202X.
10. Grassi D, Desideri G, Necozione S, Ruggieri F, Blumberg JB, Stornello M, Ferri C. Protective effects of flavanol-rich dark chocolate on endothelial function and wave reflection during acute hyperglycemia. *Hypertension* 2012;60(3):827-32. doi: 10.1161/HYPERTENSIONAHA.112.193995.
11. Bondonno CP, Yang X, Croft KD, Considine MJ, Ward NC, Rich L, Puddey IB, Swinney E, Mubarak A, Hodgson JM. Flavonoid-rich apples and nitrate-rich spinach augment nitric oxide status and improve endothelial function in healthy men and women: a randomized controlled trial. *Free Radic Biol Med* 2012;52(1):95-102. doi: S0891-5849(11)00603-4 [pii] 10.1016/j.freeradbiomed.2011.09.028.

12. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, Sies H, Kwik-Urbe C, Schmitz HH, Kelm M. (-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. *Proc Natl Acad Sci U S A* 2006;103(4):1024-9.
13. Sansone R, Rodriguez-Mateos A, Heuel J, Falk D, Schuler D, Wagstaff R, Kuhnle GG, Spencer JP, Schroeter H, Merx MW, et al. Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: a randomised, controlled, double-masked trial: the Flaviola Health Study. *Br J Nutr* 2015;114(8):1246-55. doi: 10.1017/S0007114515002822.
14. Heiss C, Sansone R, Karimi H, Krabbe M, Schuler D, Rodriguez-Mateos A, Kraemer T, Cortese-Krott MM, Kuhnle GG, Spencer JP, et al. Impact of cocoa flavanol intake on age-dependent vascular stiffness in healthy men: a randomized, controlled, double-masked trial. *Age (Dordr)* 2015;37(3):9794. doi: 10.1007/s11357-015-9794-9.
15. Dower JI, Geleijnse JM, Gijsbers L, Zock PL, Kromhout D, Hollman PC. Effects of the pure flavonoids epicatechin and quercetin on vascular function and cardiometabolic health: a randomized, double-blind, placebo-controlled, crossover trial. *Am J Clin Nutr* 2015;101(5):914-21. doi: 10.3945/ajcn.114.098590.
16. Dower JI, Geleijnse JM, Kroon PA, Philo M, Mensink M, Kromhout D, Hollman PC. Does epicatechin contribute to the acute vascular function effects of dark chocolate? A randomized, crossover study. *Mol Nutr Food Res* 2016;60(11):2379-86. doi: 10.1002/mnfr.201600045.
17. Caton PW, Potheary MR, Lees DM, Khan NQ, Wood EG, Shoji T, Kanda T, Rull G, Corder R. Regulation of vascular endothelial function by procyanidin-rich foods and beverages. *J Agric Food Chem* 2010;58(7):4008-13. doi: 10.1021/jf9031876.
18. Garcia-Conesa MT, Tribolo S, Guyot S, Tomas-Barberan FA, Kroon PA. Oligomeric procyanidins inhibit cell migration and modulate the expression of migration and proliferation associated genes in human umbilical vascular endothelial cells. *Mol Nutr Food Res* 2009;53(2):266-76. doi: 10.1002/mnfr.200800134.
19. Hollands WJ, Hart DJ, Dainty JR, Hasselwander O, Tiihonen K, Wood R, Kroon PA. Bioavailability of epicatechin and effects on nitric oxide metabolites of an apple flavanol-rich extract supplemented beverage compared to a whole apple puree: a randomized, placebo-controlled, crossover trial. *Mol Nutr Food Res* 2013;57(7):1209-17. doi: 10.1002/mnfr.201200663.
20. Hollands WJ, Voorspoels S, Jacobs G, Aaby K, Meisland A, Garcia-Villalba R, Tomas-Barberan F, Piskula MK, Mawson D, Vovk I, et al. Development, validation and evaluation of an analytical method for the determination of monomeric and oligomeric procyanidins in apple extracts. *J Chromatogr A* 2017. doi: 10.1016/j.chroma.2017.03.030.
21. Krzanowski WJ. Principles of multivariate analysis: a user's perspective. 1st ed. New York: Oxford University Press, 1988.
22. Smilde AK, Jansen JJ, Hoefsloot HC, Lamers RJ, van der Greef J, Timmerman ME. ANOVA-simultaneous component analysis (ASCA): a new tool for analyzing designed metabolomics data. *Bioinformatics* 2005;21(13):3043-8. doi: 10.1093/bioinformatics/bti476.
23. PLS Toolbox 8.01 ed. Manson, USA: Eigenvector Research, Inc, 2015.

24. Ottaviani JI, Kwik-Urbe C, Keen CL, Schroeter H. Intake of dietary procyanidins does not contribute to the pool of circulating flavanols in humans. *Am J Clin Nutr* 2012;95(4):851-8. doi: 10.3945/ajcn.111.028340.
25. Ou K, Sarnoski P, Schneider KR, Song K, Khoo C, Gu L. Microbial catabolism of procyanidins by human gut microbiota. *Mol Nutr Food Res* 2014;58(11):2196-205. doi: 10.1002/mnfr.201400243.
26. Ottaviani JI, Borges G, Momma TY, Spencer JP, Keen CL, Crozier A, Schroeter H. The metabolome of [2-(14)C](-)-epicatechin in humans: implications for the assessment of efficacy, safety, and mechanisms of action of polyphenolic bioactives. *Sci Rep* 2016;6:29034. doi: 10.1038/srep29034.
27. Ried K, Sullivan TR, Fakler P, Frank OR, Stocks NP. Effect of cocoa on blood pressure. *Cochrane Database Syst Rev* 2012(8):CD008893. doi: 10.1002/14651858.CD008893.pub2.
28. Onakpoya I, Spencer E, Heneghan C, Thompson M. The effect of green tea on blood pressure and lipid profile: a systematic review and meta-analysis of randomized clinical trials. *Nutr Metab Cardiovasc Dis* 2014;24(8):823-36. doi: 10.1016/j.numecd.2014.01.016.
29. Tokede OA, Gaziano JM, Djousse L. Effects of cocoa products/dark chocolate on serum lipids: a meta-analysis. *Eur J Clin Nutr* 2011;65(8):879-86. doi: 10.1038/ejcn.2011.64.
30. Grassi D, Desideri G, Necozione S, di Giosia P, Barnabei R, Allegaert L, Bernaert H, Ferri C. Cocoa consumption dose-dependently improves flow-mediated dilation and arterial stiffness decreasing blood pressure in healthy individuals. *J Hypertens* 2015;33(2):294-303. doi: 10.1097/HJH.0000000000000412.
31. Gasper A, Hollands W, Casgrain A, Saha S, Teucher B, Dainty JR, Venema DP, Hollman PC, Rein MJ, Nelson R, et al. Consumption of both low and high (-)-epicatechin apple puree attenuates platelet reactivity and increases plasma concentrations of nitric oxide metabolites: a randomized controlled trial. *Arch Biochem Biophys* 2014;559:29-37. doi: 10.1016/j.abb.2014.05.026.
32. Alanon ME, Castle SM, Siswanto PJ, Cifuentes-Gomez T, Spencer JP. Assessment of flavanol stereoisomers and caffeine and theobromine content in commercial chocolates. *Food Chem* 2016;208:177-84. doi: 10.1016/j.foodchem.2016.03.116.
33. Rull G, Mohd-Zain ZN, Shiel J, Lundberg MH, Collier DJ, Johnston A, Warner TD, Corder R. Effects of high flavanol dark chocolate on cardiovascular function and platelet aggregation. *Vascul Pharmacol* 2015;71:70-8. doi: 10.1016/j.vph.2015.02.010.
34. Neufingerl N, Zebregs YE, Schuring EA, Trautwein EA. Effect of cocoa and theobromine consumption on serum HDL-cholesterol concentrations: a randomized controlled trial. *Am J Clin Nutr* 2013;97(6):1201-9. doi: 10.3945/ajcn.112.047373.
35. Shechter M, Shalmon G, Scheinowitz M, Koren-Morag N, Feinberg MS, Harats D, Sela BA, Sharabi Y, Chouraqui P. Impact of acute caffeine ingestion on endothelial function in subjects with and without coronary artery disease. *Am J Cardiol* 2011;107(9):1255-61. doi: 10.1016/j.amjcard.2010.12.035.
36. Shi X, Xue W, Liang S, Zhao J, Zhang X. Acute caffeine ingestion reduces insulin sensitivity in healthy subjects: a systematic review and meta-analysis. *Nutr J* 2016;15(1):103. doi: 10.1186/s12937-016-0220-7.

37. Sansone R, Ottaviani JI, Rodriguez-Mateos A, Heinen Y, Noske D, Spencer JP, Crozier A, Merx MW, Kelm M, Schroeter H, et al. Methylxanthines enhance the effects of cocoa flavanols on cardiovascular function: randomized, double-masked controlled studies. *Am J Clin Nutr* 2017;105(2):352-60. doi: 10.3945/ajcn.116.140046.

Table 1. Mass (mg) of monomers and oligomers in apple flavanol treatments¹

Analyte	High dose	Low dose	PC
(-)-Epicatechin	125.9	62.9	6.5
(+)-Catechin	14.0	7.0	
dp2	80.0	40.0	10.3
dp3	31.6	15.8	14.3
dp4	11.4	5.7	21.9
dp5	4.2	2.1	23.7
dp6	2.3	1.2	19.1
dp7	1.2	0.6	12.7
dp8	0.0	0.0	10.3
dp9	0.0	0.0	10.4
dp10	0.0	0.0	7.4
Total procyanidins	130.7	65.4	130.1
Total flavanols	270.6	135.3	136.5

¹ The apple flavanol treatments were High dose = 140 mg monomers + 130 mg PC; Low dose = 70 mg monomers + 65 mg PC; PC = 130 mg PC. (-)-EC was the predominant monomer in the monomer rich extract (90% (-)-EC, 10% (+)-catechin). dp = degree of polymerisation, e.g. dp2 refers to an epicatechin dimer.

Table 2. Subject characteristics and biomarkers of CVD risk at baseline (n=42)

Measurement variable	Baseline value
Gender ratio (M/F)	15/27
BMI (kg/m ²)	25.9 ± 3.1 ¹
Age (yr)	63.0 ± 7.0
Office SBP (mmHg)	121 ± 9 ²
Office DBP (mmHg)	69 ± 7
Vicorder pSBP (mmHg)	128 ± 10.8
Vicorder pDBP (mmHg)	66 ± 5.4
Vicorder aSBP (mmHg)	126 ± 11
Vicorder aDBP (mmHg)	66 ± 6
Cf_PWV (m/s)	8.2 ± 1.3
Ba_PWV (m/s)	14.4 ± 1.9
AI (%)	26.8 ± 6.4
ET-1 (pg/mL)	1.1 ± 0.4
NO reaction products (µmol/L)	35.9 ± 17.0
Insulin (pmol/L)	39.8 ± 17.1
Glucose (mmol/L)	5.3 ± 0.5
Fructosamine (µmol/L)	252.2 ± 47.1
Total cholesterol (mmol/L)	6.2 ± 1.0
HDL_Cholesterol (mmol/L)	1.68 ± 0.52
LDL_Cholesterol (mmol/L)	3.91 ± 0.92
Triglycerides (mmol/L)	1.50 ± 0.95

¹Data are presented as mean ± SD (all such values)

²SBP measured at baseline was lower than that measured at eligibility assessment. This was expected because BP rises during the morning and baseline measurements were recorded earlier in the day.

Table 3. Changes in biomarkers of CVD risk, 2 h after ingestion of treatments containing either a low dose of monomeric apple flavanols, a high dose of monomeric apple flavanols, oligomeric procyanidins or placebo¹

Measurement variable	n	Low dose	High dose	Procyanidins	Placebo	P-values ²
Office SBP (mmHg)	42	6.14 ± 5.49	7.08 ± 6.11	7.79 ± 7.81	7.15 ± 6.05	0.206
Office DBP (mmHg)	42	3.03 ± 2.79	3.94 ± 3.92	2.91 ± 3.24	3.58 ± 2.74	0.444
Vicorder pSBP (mmHg)	42	6.81 ± 7.12	7.36 ± 6.75	7.17 ± 6.53	6.13 ± 6.88	0.754
Vicorder pDBP (mmHg)	42	1.91 ± 3.66	2.71 ± 3.51	1.81 ± 3.30	2.12 ± 3.28	0.849
Vicorder aSBP (mmHg)	42	6.27 ± 7.03	6.92 ± 6.67	6.82 ± 6.61	5.86 ± 6.66	0.780
Vicorder aDBP (mmHg)	42	1.76 ± 3.64	3.36 ± 5.16	1.46 ± 3.66	2.23 ± 3.31	0.381
Cf_PWV (m/s)	42	-0.04 ± 0.57	0.11 ± 0.72	-0.15 ± 1.77	0.18 ± 0.70	0.531
Ba_PWV (m/s)	42	0.35 ± 0.50	0.34 ± 0.60	0.43 ± 0.66	0.31 ± 0.68	0.869
AI (%)	42	-0.33 ± 2.92	-1.19 ± 3.26	-0.95 ± 2.39	-1.04 ± 2.85	0.351
NO reaction products (µM)	34	-4.98 ± 5.49	-4.67 ± 6.88	-3.78 ± 4.69	-5.73 ± 5.13	0.461

¹ Low dose = 70 mg monomers + 65 mg procyanidins; High dose = 140 mg monomers + 130 mg procyanidins; procyanidins = 6.5 mg monomers + 130 mg procyanidins. Data are mean ± SD (all such values)

² P values were calculated from the post – pre-differences between the four treatments using repeated measures ANOVA after excluding subjects with an incomplete set of differences. (see on-line supporting material for actual values; supplemental Table 1)

Table 4. Changes in biomarkers of CVD risk, 29 d after ingestion of treatments containing either a low dose of monomeric apple flavanols, a high dose of monomeric apple flavanols, oligomeric procyanidins or placebo¹

Measurement variable	n	Low dose	High dose	Procyanidins	Placebo	p-value ²
Office SBP (mmHg)	42	-0.39 ± 6.11	1.83 ± 6.62	2.54 ± 7.02	1.60 ± 5.04	0.076
Office DBP (mmHg)	42	-0.19 ± 3.94	1.06 ± 4.43	0.77 ± 3.90	0.55 ± 3.57	0.501
Vicorder pSBP (mmHg)	42	-1.36 ± 7.14	0.83 ± 7.72	2.07 ± 6.58	1.61 ± 7.50	0.283
Vicorder pDBP (mmHg)	42	-0.61 ± 3.41	1.04 ± 4.43	0.81 ± 4.12	0.93 ± 3.01	0.536
Vicorder aSBP (mmHg)	41	-1.44 ± 7.26	0.74 ± 7.71	2.44 ± 6.51	1.93 ± 7.33	0.155
Vicorder aDBP (mmHg)	41	-0.54 ± 3.40	1.34 ± 5.11	0.68 ± 3.93	1.09 ± 3.03	0.565
Cf_PWV (m/s)	42	-0.20 ± 0.67	-0.03 ± 0.53	-0.25 ± 1.74	0.03 ± 0.68	0.791
Ba_PWV (m/s)	41	-0.02 ± 0.63	0.30 ± 0.73	0.17 ± 0.82	0.15 ± 0.60	0.057
AI (%)	41	0.00 ± 2.35	-0.07 ± 2.88	0.24 ± 2.30	0.28 ± 2.60	0.786
NO reaction products (µM)	34	2.40 ± 24.38	9.17 ± 30.19	4.36 ± 19.08	5.03 ± 18.94	0.234
Endothelin-1 (pg/mL)	36	-0.01 ± 0.38	0.04 ± 0.38	0.09 ± 0.32	0.05 ± 0.29	0.289
Insulin (pmol/L)	36	-2.40 ± 23.05	-5.14 ± 13.02	-4.28 ± 12.38	-1.57 ± 11.65	0.339
Glucose (mmol/L)	34	-0.06 ± 0.31	-0.16 ± 0.30	-0.09 ± 0.25	0.01 ± 0.40	0.142
Fructosamine (µmol/L)	33	-1.20 ± 16.79	2.03 ± 14.83	2.71 ± 12.66	2.57 ± 25.33	0.944
Total cholesterol (mmol/L)	34	-0.13 ± 0.51	-0.01 ± 0.60	-0.03 ± 0.62	-0.05 ± 0.67	0.836
LDL cholesterol (mmol/L)	34	-0.08 ± 0.53	-0.03 ± 0.46	-0.04 ± 0.56	-0.02 ± 0.53	0.971
HDL cholesterol (mmol/L)	34	-0.03 ± 0.14	0.03 ± 0.18	0.02 ± 0.16	0.01 ± 0.25	0.674
Triglycerides (mmol/L)	34	-0.17 ± 0.49	-0.08 ± 0.37	-0.10 ± 0.43	0.06 ± 0.37	0.067

¹ Low dose = 70 mg monomers + 65 mg procyanidins; High dose = 140 mg monomers + 130 mg procyanidins; procyanidins = 6.5 mg monomers + 130 mg procyanidins. Data are mean ± SD.


² P values were calculated from the post-pre-differences between the four treatments using repeated measures ANOVA after excluding subjects with an incomplete set of differences. (See on-line supporting material for actual values; supplemental Table 2)



Figure Legends

Figure 1. Flow of participants through trial. Of the 117 participants assessed for eligibility, 74 did not meet the inclusion criteria. Eligible participants (n=43) were allocated sequentially to a treatment sequence order that was pre-determined using a block randomization approach. 1 participant dropped out of the trial part way through the first treatment phase.

Figure 2. Principal component analysis (PCA) for the metabolomic data for all participants and treatments, for both time points (A; n=32 x 4 treatments x 2-time points (day 1, day 29)) and for the ratio of post-to-pre-treatment (B; n=32 x 4 treatments).

Scores on the first two principal components are shown and the percentage variance accounted for by each component indicated on each axis. The circle represents low dose monomeric flavanol treatment, the square the high dose monomeric flavanol treatment, the triangle the placebo, and the star the procyanidin treatment. For (A), open symbols represent day 1 and closed symbols day 29 of the treatments. Six individuals are highlighted; the volunteer number is given and an ellipse shows the spread of scores for each participant) (See on-line supporting material for scores on the third and fourth principle components; supplemental Figure 1).





On line supporting material

Supplemental Table 1. Differences in biomarkers of CVD risk 2h after ingestion of treatments containing either a low dose of monomeric apple flavanols, a high dose of monomeric apple flavanols, oligomeric procyanidins or placebo

Measurement variable	n	Low dose		High dose		Procyanidins		Placebo	
		0h	2h	0h	2h	0h	2h	0h	2h
Office SBP (mmHg)	42	121 ± 10	127 ± 11	120 ± 10	127 ± 11	120 ± 9	128 ± 13	121 ± 9	128 ± 9
Office DBP (mmHg)	42	69 ± 7	72 ± 7	68 ± 7	72 ± 7	68 ± 6	71 ± 7	69 ± 7	73 ± 7
Vicorder pSBP (mmHg)	42	128 ± 11	134 ± 13	126 ± 10	134 ± 12	126 ± 10	133 ± 12	127 ± 9	133 ± 10
Vicorder pDBP (mmHg)	42	66 ± 5	68 ± 6	66 ± 6	68 ± 6	66 ± 5	68 ± 6	66 ± 5	68 ± 5
Vicorder aSBP (mmHg)	41	126 ± 11	132 ± 13	124 ± 10	131 ± 12	124 ± 10	131 ± 12	124 ± 9	130 ± 10
Vicorder aDBP (mmHg)	41	65 ± 8	67 ± 9	65 ± 6	69 ± 6	65 ± 8	67 ± 8	66 ± 5	68 ± 5
Cf_PWV (m/s)	42	8.2 ± 1.4	8.2 ± 1.4	8.1 ± 1.3	8.2 ± 1.4	8.3 ± 1.8	8.1 ± 1.5	8.1 ± 1.2	8.3 ± 1.5
Ba_PWV (m/s)	42	14.4 ± 2.0	14.7 ± 2.0	14.3 ± 1.9	14.6 ± 2.1	14.2 ± 1.9	14.7 ± 1.9	14.5 ± 2.2	14.8 ± 2.2
AI (%)	42	27 ± 6	26 ± 6	28 ± 7	26 ± 6	27 ± 6	26 ± 7	27 ± 6	26 ± 5
Nitric oxide (µM)	34	40 ± 21	31 ± 12	37 ± 20	32 ± 16	34 ± 14	30 ± 12	36 ± 14	31 ± 10

Data are presented as mean ± SD

On line supporting material

Supplemental Table 2. *Differences in biomarkers of CVD risk, 29 d after ingestion of treatments containing either a low dose of monomeric apple flavanols, a high dose of monomeric apple flavanols, oligomeric procyanidins or placebo*

Measurement variable	n	Low dose		High dose		Procyanidins		Placebo	
		0h	d29	0h	d29	0h	d29	0h	d29
Office SBP (mmHg)	42	121 ± 10	121 ± 10	120 ± 10	122 ± 10	120 ± 9	123 ± 11	121 ± 9	123 ± 9
Office DBP (mmHg)	42	69 ± 7	69 ± 7	68 ± 7	69 ± 7	68 ± 6	69 ± 7	69 ± 7	73 ± 8
Vicorder pSBP (mmHg)	42	128 ± 11	126 ± 10	126 ± 10	127 ± 11	126 ± 10	128 ± 11	127 ± 9	128 ± 10
Vicorder pDBP (mmHg)	42	66 ± 5	66 ± 6	66 ± 6	67 ± 6	66 ± 5	67 ± 6	66 ± 5	67 ± 5
Vicorder aSBP (mmHg)	41	126 ± 11	124 ± 10	124 ± 10	125 ± 11	124 ± 10	126 ± 11	124 ± 9	126 ± 10
Vicorder aDBP (mmHg)	41	65 ± 8	65 ± 9	65 ± 6	67 ± 6	65 ± 8	66 ± 8	66 ± 5	67 ± 5
Cf_PWV (m/s)	42	8.2 ± 1.4	8.0 ± 1.4	8.1 ± 1.3	8.1 ± 1.4	8.3 ± 1.8	8.0 ± 1.4	8.1 ± 1.2	8.1 ± 1.4
Ba_PWV (m/s)	41	14.4 ± 2.0	14.3 ± 2.1	14.3 ± 1.9	14.6 ± 2.3	14.2 ± 1.9	14.4 ± 2.1	14.5 ± 2.2	14.4 ± 2.0
AI (%)	41	27 ± 6	27 ± 7	28 ± 7	27 ± 6	27 ± 6	27 ± 6	27 ± 6	27 ± 5
Nitric oxide (µM)	34	40 ± 21	38 ± 20	37 ± 20	44 ± 31	34 ± 14	42 ± 36	36 ± 14	43 ± 24
Endothelin-1 (pg/mL)	36	1.11 ± 0.40	1.09 ± 0.42	1.08 ± 0.42	1.10 ± 0.43	1.12 ± 0.61	1.12 ± 0.42	1.08 ± 0.39	1.13 ± 0.38
Insulin (pmol/L)	36	41.0 ± 24.0	37.8 ± 20.9	40.9 ± 20.5	35.4 ± 17.7	40.0 ± 19.8	35.8 ± 18.3	40.4 ± 21.5	38.4 ± 18.8
Glucose (mmol/L)	34	5.3 ± 0.5	5.3 ± 0.5	5.3 ± 0.5	5.3 ± 0.4	5.3 ± 0.4	5.2 ± 0.4	5.3 ± 0.5	5.3 ± 0.5
Fructosamine (µmol/L)	33	254.5 ± 35.7	254.1 ± 37.1	253.9 ± 37.4	256.2 ± 38.0	254.0 ± 34.1	259.3 ± 37.8	253.6 ± 50.7	259.8 ± 40.6
Total cholesterol (mmol/L)	34	6.2 ± 1.0	6.1 ± 1.1	6.2 ± 0.9	6.2 ± 1.0	6.1 ± 1.0	6.1 ± 1.0	6.2 ± 1.0	6.2 ± 1.1
LDL cholesterol (mmol/L)	34	3.9 ± 0.9	3.8 ± 0.9	3.9 ± 0.9	3.9 ± 0.9	3.9 ± 0.9	3.8 ± 0.9	3.9 ± 1.0	3.9 ± 0.9
HDL cholesterol (mmol/L)	34	1.7 ± 0.5	1.6 ± 0.5	1.7 ± 0.5	1.7 ± 0.5	1.7 ± 0.5	1.7 ± 0.5	1.7 ± 0.5	1.7 ± 0.5
Triglycerides (mmol/L)	34	1.5 ± 0.7	1.4 ± 0.7	1.4 ± 0.6	1.3 ± 0.5	1.5 ± 0.8	1.3 ± 0.6	1.4 ± 0.9	1.4 ± 0.5

Data are presented as mean ± SD

ONLINE SUPPLEMENTAL MATERIAL

List of compounds observed in the Metabolon metabolomics analysis

BIOCHEMICAL	SUPER_PATHWAY	SUB_PATHWAY
1,2-dilinoeoyl-GPC (18:2/18:2)	Lipid	Phosphatidylcholine (PC)
1,2-dipalmitoyl-GPC (16:0/16:0)	Lipid	Phosphatidylcholine (PC)
1,3,7-trimethylurate	Xenobiotics	Xanthine Metabolism
1,3-dimethylurate	Xenobiotics	Xanthine Metabolism
1,5-anhydroglucitol (1,5-AG)	Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
1,7-dimethylurate	Xenobiotics	Xanthine Metabolism
1-(1-enyl-oleoyl)-2-linoeoyl-GPE (P-18:1/18:2)*	Lipid	Lysoplasmalogen
1-(1-enyl-oleoyl)-GPE (P-18:1)*	Lipid	Lysoplasmalogen
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)*	Lipid	Plasmalogen
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4)*	Lipid	Plasmalogen
1-(1-enyl-palmitoyl)-2-linoeoyl-GPC (P-16:0/18:2)*	Lipid	Plasmalogen
1-(1-enyl-palmitoyl)-2-linoeoyl-GPE (P-16:0/18:2)*	Lipid	Plasmalogen
1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)*	Lipid	Plasmalogen
1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1)*	Lipid	Plasmalogen
1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)*	Lipid	Plasmalogen
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)*	Lipid	Plasmalogen
1-(1-enyl-palmitoyl)-GPC (P-16:0)*	Lipid	Lysoplasmalogen
1-(1-enyl-palmitoyl)-GPE (P-16:0)*	Lipid	Lysoplasmalogen
1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4)*	Lipid	Plasmalogen
1-(1-enyl-stearoyl)-2-linoeoyl-GPE (P-18:0/18:2)*	Lipid	Plasmalogen
1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1)	Lipid	Plasmalogen
1-(1-enyl-stearoyl)-GPE (P-18:0)*	Lipid	Lysoplasmalogen
1-arachidonoyl-GPC (20:4n6)*	Lipid	Lysophospholipid
1-arachidonoyl-GPE (20:4n6)*	Lipid	Lysophospholipid
1-arachidonoyl-GPI (20:4)*	Lipid	Lysophospholipid
1-lignoceroyl-GPC (24:0)	Lipid	Lysophospholipid
1-linolenoyl-GPC (18:3)*	Lipid	Lysophospholipid
1-linoeoyl-2-arachidonoyl-GPC (18:2/20:4n6)*	Lipid	Phosphatidylcholine (PC)
1-linoeoyl-2-linolenoyl-GPC (18:2/18:3)*	Lipid	Phosphatidylcholine (PC)
1-linoeoyl-GPC (18:2)	Lipid	Lysophospholipid
1-linoeoyl-GPE (18:2)*	Lipid	Lysophospholipid
1-linoeoyl-GPI (18:2)*	Lipid	Lysophospholipid
1-methylguanidine	Amino Acid	Guanidino and Acetamido Metabolism
1-methylhistidine	Amino Acid	Histidine Metabolism
1-methylimidazoleacetate	Amino Acid	Histidine Metabolism
1-methylnicotinamide	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism
1-methylurate	Xenobiotics	Xanthine Metabolism
1-methylxanthine	Xenobiotics	Xanthine Metabolism
1-oleoyl-2-arachidonoyl-GPE (18:1/20:4)*	Lipid	Phosphatidylethanolamine (PE)
1-oleoyl-2-linoeoyl-GPE (18:1/18:2)*	Lipid	Phosphatidylethanolamine (PE)
1-oleoyl-2-linoeoyl-GPI (18:1/18:2)*	Lipid	Phosphatidylinositol (PI)
1-oleoyl-GPC (18:1)	Lipid	Lysophospholipid
1-oleoyl-GPE (18:1)	Lipid	Lysophospholipid
1-oleoyl-GPI (18:1)*	Lipid	Lysophospholipid
1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3)*	Lipid	Phosphatidylcholine (PC)
1-palmitoleoyl-2-linoeoyl-GPC (16:1/18:2)*	Lipid	Phosphatidylcholine (PC)
1-palmitoleoyl-GPC (16:1)*	Lipid	Lysophospholipid
1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6)	Lipid	Phosphatidylcholine (PC)
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)*	Lipid	Phosphatidylethanolamine (PE)
1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)*	Lipid	Phosphatidylinositol (PI)
1-palmitoyl-2-gamma-linolenoyl-GPC (16:0/18:3n6)*	Lipid	Phosphatidylcholine (PC)
1-palmitoyl-2-linoeoyl-GPC (16:0/18:2)	Lipid	Phosphatidylcholine (PC)
1-palmitoyl-2-linoeoyl-GPE (16:0/18:2)	Lipid	Phosphatidylethanolamine (PE)
1-palmitoyl-2-oleoyl-GPC (16:0/18:1)	Lipid	Phosphatidylcholine (PC)
1-palmitoyl-2-oleoyl-GPE (16:0/18:1)	Lipid	Phosphatidylethanolamine (PE)
1-palmitoyl-2-oleoyl-GPI (16:0/18:1)*	Lipid	Phosphatidylinositol (PI)
1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)*	Lipid	Phosphatidylcholine (PC)
1-palmitoyl-2-stearoyl-GPC (16:0/18:0)	Lipid	Phosphatidylcholine (PC)
1-palmitoyl-GPC (16:0)	Lipid	Lysophospholipid
1-palmitoyl-GPE (16:0)	Lipid	Lysophospholipid
1-palmitoyl-GPI (16:0)	Lipid	Lysophospholipid
1-stearoyl-2-arachidonoyl-GPC (18:0/20:4)	Lipid	Phosphatidylcholine (PC)
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4)	Lipid	Phosphatidylethanolamine (PE)
1-stearoyl-2-arachidonoyl-GPI (18:0/20:4)	Lipid	Phosphatidylinositol (PI)
1-stearoyl-2-arachidonoyl-GPS (18:0/20:4)	Lipid	Phosphatidylserine (PS)
1-stearoyl-2-linoeoyl-GPC (18:0/18:2)*	Lipid	Phosphatidylcholine (PC)
1-stearoyl-2-linoeoyl-GPE (18:0/18:2)*	Lipid	Phosphatidylethanolamine (PE)
1-stearoyl-2-linoeoyl-GPI (18:0/18:2)	Lipid	Phosphatidylinositol (PI)
1-stearoyl-2-oleoyl-GPC (18:0/18:1)	Lipid	Phosphatidylcholine (PC)
1-stearoyl-2-oleoyl-GPE (18:0/18:1)	Lipid	Phosphatidylethanolamine (PE)
1-stearoyl-2-oleoyl-GPI (18:0/18:1)*	Lipid	Phosphatidylinositol (PI)
1-stearoyl-2-oleoyl-GPS (18:0/18:1)	Lipid	Phosphatidylserine (PS)
1-stearoyl-GPC (18:0)	Lipid	Lysophospholipid
1-stearoyl-GPE (18:0)	Lipid	Lysophospholipid
1-stearoyl-GPI (18:0)	Lipid	Lysophospholipid
10-undecenoate (11:1n1)	Lipid	Medium Chain Fatty Acid
13-HODE + 9-HODE	Lipid	Fatty Acid, Monohydroxy

16a-hydroxy DHEA 3-sulfate	Lipid	Steroid
18-hydroxycorticosterone	Lipid	Steroid
2'-deoxyuridine	Nucleotide	Pyrimidine Metabolism, Uracil containing
2'-O-methylcytidine	Nucleotide	Pyrimidine Metabolism, Cytidine containing
2'-O-methyluridine	Nucleotide	Pyrimidine Metabolism, Uracil containing
2,3-dihydroxy-2-methylbutyrate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
2,3-dihydroxyisovalerate	Xenobiotics	Food Component/Plant
2-acetamidophenol sulfate	Xenobiotics	Drug
2-aminoadipate	Amino Acid	Lysine Metabolism
2-aminobutyrate	Amino Acid	Glutathione Metabolism
2-aminoheptanoate	Lipid	Fatty Acid, Amino
2-aminooctanoate	Lipid	Fatty Acid, Amino
2-aminophenol sulfate	Xenobiotics	Chemical
2-hydroxy-3-methylvalerate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
2-hydroxyacetaminophen sulfate*	Xenobiotics	Drug
2-hydroxybutyrate/2-hydroxyisobutyrate	Amino Acid	Glutathione Metabolism
2-hydroxyglutarate	Lipid	Fatty Acid, Dicarboxylate
2-hydroxyhippurate (salicylurate)	Xenobiotics	Benzoate Metabolism
2-hydroxyibuprofen	Xenobiotics	Drug
2-hydroxyoctanoate	Lipid	Fatty Acid, Monohydroxy
2-hydroxyphenylacetate	Amino Acid	Tyrosine Metabolism
2-methoxyacetaminophen glucuronide*	Xenobiotics	Drug
2-methoxyacetaminophen sulfate*	Xenobiotics	Drug
2-methoxyresorcinol sulfate	Xenobiotics	Chemical
2-methylbutyrylcarnitine (C5)	Amino Acid	Leucine, Isoleucine and Valine Metabolism
2-methylbutyrylglycine	Amino Acid	Leucine, Isoleucine and Valine Metabolism
2-oxindole-3-acetate	Xenobiotics	Food Component/Plant
2-oxoarginine*	Amino Acid	Urea cycle; Arginine and Proline Metabolism
2-palmitoyl-GPC (16:0)*	Lipid	Lysophospholipid
2-piperidinone	Xenobiotics	Food Component/Plant
2-stearoyl-GPE (18:0)*	Lipid	Lysophospholipid
21-hydroxypregnenolone disulfate	Lipid	Steroid
3,7-dimethylurate	Xenobiotics	Xanthine Metabolism
3-(3-hydroxyphenyl)propionate	Xenobiotics	Benzoate Metabolism
3-(4-hydroxyphenyl)lactate	Amino Acid	Tyrosine Metabolism
3-(cystein-S-yl)acetaminophen*	Xenobiotics	Drug
3-(N-acetyl-L-cystein-S-yl) acetaminophen	Xenobiotics	Drug
3-aminoisobutyrate	Nucleotide	Pyrimidine Metabolism, Thymine containing
3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF)	Lipid	Fatty Acid, Dicarboxylate
3-hydroxy-2-ethylpropionate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
3-hydroxy-3-methylglutarate	Lipid	Mevalonate Metabolism
3-hydroxybutyrate (BHBA)	Lipid	Ketone Bodies
3-hydroxybutyrylcarnitine (1)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
3-hydroxybutyrylcarnitine (2)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
3-hydroxyhexanoate	Lipid	Fatty Acid, Monohydroxy
3-hydroxyhippurate	Xenobiotics	Benzoate Metabolism
3-hydroxyisobutyrate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
3-hydroxyoctanoate	Lipid	Fatty Acid, Monohydroxy
3-hydroxypyridine sulfate	Xenobiotics	Chemical
3-hydroxyquinine	Xenobiotics	Drug
3-indoxyl sulfate	Amino Acid	Tryptophan Metabolism
3-methoxycatechol sulfate (1)	Xenobiotics	Benzoate Metabolism
3-methoxytyrosine	Amino Acid	Tyrosine Metabolism
3-methyl catechol sulfate (1)	Xenobiotics	Benzoate Metabolism
3-methyl-2-oxobutyrate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
3-methyl-2-oxovalerate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
3-methyladipate	Lipid	Fatty Acid, Dicarboxylate
3-methylcytidine	Nucleotide	Pyrimidine Metabolism, Cytidine containing
3-methylglutaconate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
3-methylglutaryl carnitine (2)	Amino Acid	Leucine, Isoleucine and Valine Metabolism
3-methylhistidine	Amino Acid	Histidine Metabolism
3-methylxanthine	Xenobiotics	Xanthine Metabolism
3-phenylpropionate (hydrocinnamate)	Xenobiotics	Benzoate Metabolism
3-ureidopropionate	Nucleotide	Pyrimidine Metabolism, Uracil containing
3beta-hydroxy-5-cholestenoate	Lipid	Sterol
4-acetamidobutanoate	Amino Acid	Polyamine Metabolism
4-acetamidophenol	Xenobiotics	Drug
4-acetamidophenylglucuronide	Xenobiotics	Drug
4-acetaminophen sulfate	Xenobiotics	Drug
4-allylphenol sulfate	Xenobiotics	Food Component/Plant
4-aminophenol sulfate (2)	Xenobiotics	Drug
4-cholesten-3-one	Lipid	Sterol
4-ethylphenylsulfate	Xenobiotics	Benzoate Metabolism
4-guanidinobutanoate	Amino Acid	Guanidino and Acetamido Metabolism
4-hydroxychlorothalonil	Xenobiotics	Chemical
4-hydroxycinnamate sulfate	Amino Acid	Tyrosine Metabolism
4-hydroxycoumarin	Xenobiotics	Drug
4-hydroxyglutamate	Amino Acid	Glutamate Metabolism
4-hydroxyhippurate	Xenobiotics	Benzoate Metabolism
4-hydroxyphenylacetylglutamine	Peptide	Acetylated Peptides
4-methyl-2-oxopentanoate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
4-methylcatechol sulfate	Xenobiotics	Benzoate Metabolism

4-vinylphenol sulfate	Xenobiotics	Benzoate Metabolism
5,6-dihydrothymine	Nucleotide	Pyrimidine Metabolism, Thymine containing
5,6-dihydrouracil	Nucleotide	Pyrimidine Metabolism, Uracil containing
5-(galactosylhydroxy)-L-lysine	Amino Acid	Lysine Metabolism
5-acetylamino-6-amino-3-methyluracil	Xenobiotics	Xanthine Metabolism
5-acetylamino-6-formylamino-3-methyluracil	Xenobiotics	Xanthine Metabolism
5-bromotryptophan	Amino Acid	Tryptophan Metabolism
5-hydroxyhexanoate	Lipid	Fatty Acid, Monohydroxy
5-hydroxylysine	Amino Acid	Lysine Metabolism
5-methylthioadenosine (MTA)	Amino Acid	Polyamine Metabolism
5-methyluridine (ribothymidine)	Nucleotide	Pyrimidine Metabolism, Uracil containing
5-oxoproline	Amino Acid	Glutathione Metabolism
5alpha-androstan-3alpha,17beta-diol disulfate	Lipid	Steroid
5alpha-androstan-3alpha,17beta-diol monosulfate (1)	Lipid	Steroid
5alpha-androstan-3alpha,17beta-diol monosulfate (2)	Lipid	Steroid
5alpha-androstan-3beta,17alpha-diol disulfate	Lipid	Steroid
5alpha-androstan-3beta,17beta-diol disulfate	Lipid	Steroid
5alpha-androstan-3beta,17beta-diol monosulfate (2)	Lipid	Steroid
5alpha-pregnan-3beta,20alpha-diol disulfate	Lipid	Steroid
5alpha-pregnan-3beta,20alpha-diol monosulfate (2)	Lipid	Steroid
5alpha-pregnan-3beta,20beta-diol monosulfate (1)	Lipid	Steroid
6-hydroxyindole sulfate	Xenobiotics	Chemical
6-oxopiperidine-2-carboxylate	Amino Acid	Lysine Metabolism
7-alpha-hydroxy-3-oxo-4-cholestenoate (7-Hoca)	Lipid	Sterol
7-methylguanine	Nucleotide	Purine Metabolism, Guanine containing
7-methylurate	Xenobiotics	Xanthine Metabolism
7-methylxanthine	Xenobiotics	Xanthine Metabolism
acesulfame	Xenobiotics	Food Component/Plant
acetylcarnitine (C2)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
acisoga	Amino Acid	Polyamine Metabolism
aconitate [cis or trans]	Energy	TCA Cycle
adenine	Nucleotide	Purine Metabolism, Adenine containing
adenosine 3',5'-cyclic monophosphate (cAMP)	Nucleotide	Purine Metabolism, Adenine containing
adenosine 5'-monophosphate (AMP)	Nucleotide	Purine Metabolism, Adenine containing
adipoylcarnitine (C6-DC)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
adrenate (22:4n6)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
adrenoylcarnitine (C22:4)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
alanine	Amino Acid	Alanine and Aspartate Metabolism
allantoin	Nucleotide	Purine Metabolism, (Hypo)Xanthine/Inosine containing
alliin	Xenobiotics	Food Component/Plant
alpha-hydroxyisocaproate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
alpha-hydroxyisovalerate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
alpha-ketobutyrate	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
alpha-ketoglutarate	Energy	TCA Cycle
alpha-tocopherol	Cofactors and Vitamins	Tocopherol Metabolism
andro steroid monosulfate (1)*	Lipid	Steroid
androstenediol (3alpha, 17alpha) monosulfate (2)	Lipid	Steroid
androstenediol (3alpha, 17alpha) monosulfate (3)	Lipid	Steroid
androstenediol (3beta,17beta) disulfate (1)	Lipid	Steroid
androstenediol (3beta,17beta) disulfate (2)	Lipid	Steroid
androstenediol (3beta,17beta) monosulfate (1)	Lipid	Steroid
androstenediol (3beta,17beta) monosulfate (2)	Lipid	Steroid
androsterone sulfate	Lipid	Steroid
arabinose	Carbohydrate	Pentose Metabolism
arabitol/xylitol	Carbohydrate	Pentose Metabolism
arabonate/xylonate	Carbohydrate	Pentose Metabolism
arachidonate (20:4n6)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
arachidonoylcarnitine (C20:4)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
arachidonoylcholine	Lipid	Fatty Acid Metabolism (Acyl Choline)
arachidoylcarnitine (C20)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
argininate*	Amino Acid	Urea cycle; Arginine and Proline Metabolism
arginine	Amino Acid	Urea cycle; Arginine and Proline Metabolism
asparagine	Amino Acid	Alanine and Aspartate Metabolism
aspartate	Amino Acid	Alanine and Aspartate Metabolism
behenoyl dihydro sphingomyelin (d18:0/22:0)*	Lipid	Sphingolipid Metabolism
behenoyl sphingomyelin (d18:1/22:0)*	Lipid	Sphingolipid Metabolism
behenoylcarnitine (C22)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
benzoate	Xenobiotics	Benzoate Metabolism
benzoylcarnitine*	Xenobiotics	Chemical
beta-citrylglutamate	Amino Acid	Glutamate Metabolism
beta-cryptoxanthin	Xenobiotics	Food Component/Plant
beta-guanidinopropanoate	Xenobiotics	Food Component/Plant
beta-hydroxyisovalerate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
beta-sitosterol	Lipid	Sterol
betaine	Amino Acid	Glycine, Serine and Threonine Metabolism
betonicine	Xenobiotics	Food Component/Plant
bilirubin (E,E)*	Cofactors and Vitamins	Hemoglobin and Porphyrin Metabolism
bilirubin (E,Z or Z,E)*	Cofactors and Vitamins	Hemoglobin and Porphyrin Metabolism
bilirubin (Z,Z)	Cofactors and Vitamins	Hemoglobin and Porphyrin Metabolism
biliverdin	Cofactors and Vitamins	Hemoglobin and Porphyrin Metabolism
butyrylcarnitine (C4)	Lipid	Fatty Acid Metabolism (also BCAA Metabolism)
C-glycosyltryptophan	Amino Acid	Tryptophan Metabolism

caffeic acid sulfate	Xenobiotics	Xanthine Metabolism
caffeine	Xenobiotics	Xanthine Metabolism
campesterol	Lipid	Sterol
caproate (6:0)	Lipid	Medium Chain Fatty Acid
caprylate (8:0)	Lipid	Medium Chain Fatty Acid
carboxyethyl-GABA	Amino Acid	Glutamate Metabolism
carboxyibuprofen	Xenobiotics	Drug
carnitine	Lipid	Carnitine Metabolism
carotene diol (1)	Xenobiotics	Food Component/Plant
carotene diol (2)	Xenobiotics	Food Component/Plant
carotene diol (3)	Xenobiotics	Food Component/Plant
catechol sulfate	Xenobiotics	Benzoate Metabolism
ceramide (d18:1/14:0, d16:1/16:0)*	Lipid	Ceramides
ceramide (d18:1/17:0, d17:1/18:0)*	Lipid	Ceramides
ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0)*	Lipid	Ceramides
cerotoylcarnitine (C26)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
cetirizine	Xenobiotics	Drug
chenodeoxycholate	Lipid	Primary Bile Acid Metabolism
chiro-inositol	Lipid	Inositol Metabolism
cholate	Lipid	Primary Bile Acid Metabolism
cholesterol	Lipid	Sterol
choline	Lipid	Phospholipid Metabolism
choline phosphate	Lipid	Phospholipid Metabolism
cinnamoylglycine	Xenobiotics	Food Component/Plant
cis-4-decenoylcarnitine (C10:1)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
citrate	Energy	TCA Cycle
citrulline	Amino Acid	Urea cycle; Arginine and Proline Metabolism
cortisol	Lipid	Steroid
cortisone	Lipid	Steroid
creatine	Amino Acid	Creatine Metabolism
creatinine	Amino Acid	Creatine Metabolism
cys-gly, oxidized	Amino Acid	Glutathione Metabolism
cystathionine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
cysteine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
cysteine s-sulfate	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
cysteine sulfinic acid	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
cysteine-glutathione disulfide	Amino Acid	Glutathione Metabolism
cysteinylglycine	Amino Acid	Glutathione Metabolism
cystine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
cytidine	Nucleotide	Pyrimidine Metabolism, Cytidine containing
decanoylcarnitine (C10)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
dehydroisoandrosterone sulfate (DHEA-S)	Lipid	Steroid
deoxycarnitine	Lipid	Carnitine Metabolism
deoxycholate	Lipid	Secondary Bile Acid Metabolism
desmethylnaproxen	Xenobiotics	Drug
desmethylnaproxen sulfate	Xenobiotics	Drug
diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [1]*	Lipid	Diacylglycerol
diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [2]*	Lipid	Diacylglycerol
diacylglycerol (14:0/18:1, 16:0/16:1) [1]*	Lipid	Diacylglycerol
diacylglycerol (14:0/18:1, 16:0/16:1) [2]*	Lipid	Diacylglycerol
diacylglycerol (16:1/18:2 [2], 16:0/18:3 [1])*	Lipid	Diacylglycerol
dihomo-linolenate (20:3n3 or n6)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
dihomo-linolenoyl-choline	Lipid	Fatty Acid Metabolism (Acyl Choline)
dihomo-linolenoylcarnitine (20:3n3 or 6)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
dihomo-linoleoylcarnitine (C20:2)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
dihydrorootate	Nucleotide	Pyrimidine Metabolism, Orotate containing
dimethyl sulfone	Xenobiotics	Chemical
dimethylarginine (SDMA + ADMA)	Amino Acid	Urea cycle; Arginine and Proline Metabolism
dimethylglycine	Amino Acid	Glycine, Serine and Threonine Metabolism
docosahexaenoate (DHA; 22:6n3)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
docosahexaenoylcarnitine (C22:6)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
docosahexaenoylcholine	Lipid	Fatty Acid Metabolism (Acyl Choline)
docosapentaenoate (n3 DPA; 22:5n3)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
docosapentaenoylcarnitine (C22:5n3)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
docosatrenoate (22:3n3)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
dodecanedioate	Lipid	Fatty Acid, Dicarboxylate
dopamine 3-O-sulfate	Amino Acid	Tyrosine Metabolism
DSGEGDFXAEAGGVR*	Peptide	Fibrinogen Cleavage Peptide
ectoine	Xenobiotics	Chemical
EDTA	Xenobiotics	Chemical
eicosapentaenoate (EPA; 20:5n3)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
eicosapentaenoylcholine	Lipid	Fatty Acid Metabolism (Acyl Choline)
eicosenoate (20:1)	Lipid	Long Chain Fatty Acid
eicosenoylcarnitine (C20:1)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
epiandrosterone sulfate	Lipid	Steroid
ergothioneine	Xenobiotics	Food Component/Plant
erythritol	Xenobiotics	Food Component/Plant
erythronate*	Carbohydrate	Aminosugar Metabolism
ethyl glucuronide	Xenobiotics	Chemical
ethyl paraben sulfate	Xenobiotics	Chemical
ethylmalonate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
etiocolanolone glucuronide	Lipid	Steroid


eugenol sulfate	Xenobiotics	Food Component/Plant
formiminoglutamate	Amino Acid	Histidine Metabolism
fructose	Carbohydrate	Fructose, Mannose and Galactose Metabolism
gamma-carboxyglutamate	Amino Acid	Glutamate Metabolism
gamma-CEHC	Cofactors and Vitamins	Tocopherol Metabolism
gamma-glutamyl-2-aminobutyrate	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamyl-alpha-lysine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamyl-epsilon-lysine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylalanine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylglutamate	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylglutamine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylglycine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylhistidine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylisoleucine*	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylleucine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylmethionine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylphenylalanine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylthreonine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamyltryptophan	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamyltyrosine	Peptide	Gamma-glutamyl Amino Acid
gamma-glutamylvaline	Peptide	Gamma-glutamyl Amino Acid
gamma-tocopherol/beta-tocopherol	Cofactors and Vitamins	Tocopherol Metabolism
gentisate	Amino Acid	Tyrosine Metabolism
gluconate	Xenobiotics	Food Component/Plant
glucose	Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
glucuronate	Carbohydrate	Aminosugar Metabolism
glutamate	Amino Acid	Glutamate Metabolism
glutamine	Amino Acid	Glutamate Metabolism
glutaryl carnitine (C5-DC)	Amino Acid	Lysine Metabolism
glycerate	Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
glycerol	Lipid	Glycerolipid Metabolism
glycerol 3-phosphate	Lipid	Glycerolipid Metabolism
glycerophosphoethanolamine	Lipid	Phospholipid Metabolism
glycerophosphoglycerol	Lipid	Glycerolipid Metabolism
glycerophosphoinositol*	Lipid	Phospholipid Metabolism
glycerophosphorylcholine (GPC)	Lipid	Phospholipid Metabolism
glycine	Amino Acid	Glycine, Serine and Threonine Metabolism
glycochenodeoxycholate	Lipid	Primary Bile Acid Metabolism
glycochenodeoxycholate glucuronide (1)	Lipid	Primary Bile Acid Metabolism
glycochenodeoxycholate sulfate	Lipid	Primary Bile Acid Metabolism
glycocholate	Lipid	Primary Bile Acid Metabolism
glycocholate sulfate*	Lipid	Secondary Bile Acid Metabolism
glycodeoxycholate	Lipid	Secondary Bile Acid Metabolism
glycodeoxycholate sulfate	Lipid	Secondary Bile Acid Metabolism
glycolithocholate sulfate*	Lipid	Secondary Bile Acid Metabolism
glycosyl ceramide (d18:1/20:0, d16:1/22:0)*	Lipid	Ceramides
glycosyl ceramide (d18:1/23:1, d17:1/24:1)*	Lipid	Ceramides
glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)*	Lipid	Sphingolipid Metabolism
glycosyl-N-palmitoyl-sphingosine (d18:1/16:0)	Lipid	Sphingolipid Metabolism
glycosyl-N-stearoyl-sphingosine (d18:1/18:0)	Lipid	Sphingolipid Metabolism
glycoursodeoxycholate	Lipid	Secondary Bile Acid Metabolism
guanidinoacetate	Amino Acid	Creatine Metabolism
guanosine	Nucleotide	Purine Metabolism, Guanine containing
gulonate*	Cofactors and Vitamins	Ascorbate and Aldarate Metabolism
heptanoate (7:0)	Lipid	Medium Chain Fatty Acid
hexanoylcarnitine (C6)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
hexanoylglutamine	Lipid	Fatty Acid Metabolism (Acyl Glutamine)
hippurate	Xenobiotics	Benzoate Metabolism
histidine	Amino Acid	Histidine Metabolism
homoarginine	Amino Acid	Urea cycle; Arginine and Proline Metabolism
homocitrulline	Amino Acid	Urea cycle; Arginine and Proline Metabolism
homostachydrine*	Xenobiotics	Food Component/Plant
hydantoin-5-propionic acid	Amino Acid	Histidine Metabolism
hydroquinone sulfate	Xenobiotics	Drug
hyocholate	Lipid	Secondary Bile Acid Metabolism
hypotaurine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
hypoxanthine	Nucleotide	Purine Metabolism, (Hypo)Xanthine/Inosine containing
ibuprofen	Xenobiotics	Drug
ibuprofen acyl glucuronide	Xenobiotics	Drug
imidazole lactate	Amino Acid	Histidine Metabolism
imidazole propionate	Amino Acid	Histidine Metabolism
iminodiacetate (IDA)	Xenobiotics	Chemical
indoleacetate	Amino Acid	Tryptophan Metabolism
indoleacetylglutamine	Amino Acid	Tryptophan Metabolism
indolelactate	Amino Acid	Tryptophan Metabolism
indolepropionate	Amino Acid	Tryptophan Metabolism
indolin-2-one	Xenobiotics	Food Component/Plant
inosine	Nucleotide	Purine Metabolism, (Hypo)Xanthine/Inosine containing
isobutyrylcarnitine (C4)	Amino Acid	Leucine, Isoleucine and Valine Metabolism
isobutyryl glycine	Amino Acid	Leucine, Isoleucine and Valine Metabolism
isoleucine	Amino Acid	Leucine, Isoleucine and Valine Metabolism
isoursodeoxycholate	Lipid	Secondary Bile Acid Metabolism

isovalerylcarnitine (C5)	Amino Acid	Leucine, Isoleucine and Valine Metabolism
isovalerylglycine	Amino Acid	Leucine, Isoleucine and Valine Metabolism
kynurenate	Amino Acid	Tryptophan Metabolism
kynurenine	Amino Acid	Tryptophan Metabolism
L-urobilin	Cofactors and Vitamins	Hemoglobin and Porphyrin Metabolism
lactate	Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
lactosyl-N-nervonoyl-sphingosine (d18:1/24:1)*	Lipid	Sphingolipid Metabolism
lactosyl-N-palmitoyl-sphingosine (d18:1/16:0)	Lipid	Sphingolipid Metabolism
lanthionine	Xenobiotics	Chemical
laurylcarnitine (C12)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
leucine	Amino Acid	Leucine, Isoleucine and Valine Metabolism
lignoceroyl sphingomyelin (d18:1/24:0)	Lipid	Sphingolipid Metabolism
lignoceroylcarnitine (C24)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
linoleate (18:2n6)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
linolenate [alpha or gamma; (18:3n3 or 6)]	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
linolenoylcarnitine (C18:3)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1]*	Lipid	Diacylglycerol
linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2]*	Lipid	Diacylglycerol
linoleoyl-docosahexaenoyl-glycerol (18:2/22:6) [2]*	Lipid	Diacylglycerol
linoleoyl-linolenoyl-glycerol (18:2/18:3) [2]*	Lipid	Diacylglycerol
linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]*	Lipid	Diacylglycerol
linoleoylcarnitine (C18:2)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
linoleoylcholine*	Lipid	Fatty Acid Metabolism (Acyl Choline)
lysine	Amino Acid	Lysine Metabolism
malate	Energy	TCA Cycle
maleate	Lipid	Fatty Acid, Dicarboxylate
malonate	Lipid	Fatty Acid Synthesis
maltotriose	Carbohydrate	Glycogen Metabolism
mannitol/sorbitol	Carbohydrate	Fructose, Mannose and Galactose Metabolism
mannose	Carbohydrate	Fructose, Mannose and Galactose Metabolism
margaroylcarnitine*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
methionine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
methionine sulfone	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
methionine sulfoxide	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
methyl glucopyranoside (alpha + beta)	Xenobiotics	Food Component/Plant
methyl indole-3-acetate	Xenobiotics	Food Component/Plant
methyl-4-hydroxybenzoate sulfate	Xenobiotics	Benzoate Metabolism
methylsuccinate	Amino Acid	Leucine, Isoleucine and Valine Metabolism
myo-inositol	Lipid	Inositol Metabolism
myristoleoylcarnitine (C14:1)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
myristoyl dihydrosphingomyelin (d18:0/14:0)*	Lipid	Sphingolipid Metabolism
myristoylcarnitine (C14)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
N(1)-acetylspermidine	Amino Acid	Polyamine Metabolism
N-(2-furoyl)glycine	Xenobiotics	Food Component/Plant
N-acetyl-1-methylhistidine*	Amino Acid	Histidine Metabolism
N-acetyl-3-methylhistidine*	Amino Acid	Histidine Metabolism
N-acetyl-aspartyl-glutamate (NAAG)	Amino Acid	Glutamate Metabolism
N-acetyl-beta-alanine	Nucleotide	Pyrimidine Metabolism, Uracil containing
N-acetylalanine	Amino Acid	Alanine and Aspartate Metabolism
N-acetyllaiiin	Xenobiotics	Food Component/Plant
N-acetylarginine	Amino Acid	Urea cycle; Arginine and Proline Metabolism
N-acetylaspartate (NAA)	Amino Acid	Alanine and Aspartate Metabolism
N-acetylcarnosine	Peptide	Dipeptide Derivative
N-acetylcitrulline	Amino Acid	Urea cycle; Arginine and Proline Metabolism
N-acetylglucosamine/N-acetylgalactosamine	Carbohydrate	Aminosugar Metabolism
N-acetylglucosaminylasparagine	Carbohydrate	Aminosugar Metabolism
N-acetylglutamate	Amino Acid	Glutamate Metabolism
N-acetylglutamine	Amino Acid	Glutamate Metabolism
N-acetyl glycine	Amino Acid	Glycine, Serine and Threonine Metabolism
N-acetylhistidine	Amino Acid	Histidine Metabolism
N-acetylkynurenine (2)	Amino Acid	Tryptophan Metabolism
N-acetylleucine	Amino Acid	Leucine, Isoleucine and Valine Metabolism
N-acetylmethionine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
N-acetylneuraminate	Carbohydrate	Aminosugar Metabolism
N-acetylphenylalanine	Amino Acid	Phenylalanine Metabolism
N-acetylproline	Amino Acid	Urea cycle; Arginine and Proline Metabolism
N-acetylputrescine	Amino Acid	Polyamine Metabolism
N-acetylserine	Amino Acid	Glycine, Serine and Threonine Metabolism
N-acetyltaurine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
N-acetylthreonine	Amino Acid	Glycine, Serine and Threonine Metabolism
N-acetyltryptophan	Amino Acid	Tryptophan Metabolism
N-acetyltyrosine	Amino Acid	Tyrosine Metabolism
N-acetylvaline	Amino Acid	Leucine, Isoleucine and Valine Metabolism
N-behenoyl-sphingadienine (d18:2/22:0)*	Lipid	Sphingolipid Metabolism
N-delta-acetylornithine	Amino Acid	Urea cycle; Arginine and Proline Metabolism
N-formylmethionine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
N-methylproline	Amino Acid	Urea cycle; Arginine and Proline Metabolism
N-methyltaurine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
N-nervonoyl-hexadecaspingosine (d16:1/24:1)*	Lipid	Sphingolipid Metabolism
N-nervonoyl-sphingadiene (d18:2/24:1)*	Lipid	Sphingolipid Metabolism
N-palmitoyl-sphinganine (d18:0/16:0)	Lipid	Sphingolipid Metabolism
N-palmitoyl-sphingosine (d18:1/16:0)	Lipid	Sphingolipid Metabolism

N-stearoyl-sphingosine (d18:1/18:0)*	Lipid	Sphingolipid Metabolism
N-trimethyl 5-aminovalerate	Amino Acid	Lysine Metabolism
N1-Methyl-2-pyridone-5-carboxamide	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism
N1-Methyl-4-pyridone-3-carboxamide	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism
N1-methyladenosine	Nucleotide	Purine Metabolism, Adenine containing
N1-methylinosine	Nucleotide	Purine Metabolism, (Hypo)Xanthine/inosine containing
N2,N2-dimethylguanosine	Nucleotide	Purine Metabolism, Guanine containing
N2,N5-diacetylornithine	Amino Acid	Urea cycle; Arginine and Proline Metabolism
N6,N6,N6-trimethyllysine	Amino Acid	Lysine Metabolism
N6-acetyllysine	Amino Acid	Lysine Metabolism
N6-carbamoylthreonyladenosine	Nucleotide	Purine Metabolism, Adenine containing
N6-carboxymethyllysine	Carbohydrate	Advanced Glycation End-product
N6-methyladenosine	Nucleotide	Purine Metabolism, Adenine containing
N6-succinyladenosine	Nucleotide	Purine Metabolism, Adenine containing
naproxen	Xenobiotics	Drug
nervonate (24:1n9)*	Lipid	Long Chain Fatty Acid
nervonylcarnitine (C24:1)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
nicotinamide	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism
O-acetylhomoserine	Amino Acid	Glycine, Serine and Threonine Metabolism
O-methylcatechol sulfate	Xenobiotics	Benzoate Metabolism
O-sulfo-L-tyrosine	Xenobiotics	Chemical
octanoylcarnitine (C8)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
oleate/vaccenate (18:1)	Lipid	Long Chain Fatty Acid
oleoyl ethanolamide	Lipid	Endocannabinoid
oleoyl-arachidonoyl-glycerol (18:1/20:4) [1]*	Lipid	Diacylglycerol
oleoyl-arachidonoyl-glycerol (18:1/20:4) [2]*	Lipid	Diacylglycerol
oleoyl-linolenoyl-glycerol (18:1/18:3) [2]*	Lipid	Diacylglycerol
oleoyl-linoleoyl-glycerol (18:1/18:2) [1]	Lipid	Diacylglycerol
oleoyl-linoleoyl-glycerol (18:1/18:2) [2]	Lipid	Diacylglycerol
oleoyl-oleoyl-glycerol (18:1/18:1) [1]*	Lipid	Diacylglycerol
oleoyl-oleoyl-glycerol (18:1/18:1) [2]*	Lipid	Diacylglycerol
oleoylcarnitine (C18:1)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
oleoylcholine	Lipid	Fatty Acid Metabolism (Acyl Choline)
ornithine	Amino Acid	Urea cycle; Arginine and Proline Metabolism
orotate	Nucleotide	Pyrimidine Metabolism, Orotate containing
orotidine	Nucleotide	Pyrimidine Metabolism, Orotate containing
oxalate (ethanedioate)	Cofactors and Vitamins	Ascorbate and Aldarate Metabolism
p-cresol sulfate	Xenobiotics	Benzoate Metabolism
p-cresol-glucuronide*	Amino Acid	Tyrosine Metabolism
palmitoleoyl-arachidonoyl-glycerol (16:1/20:4) [2]*	Lipid	Diacylglycerol
palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1]*	Lipid	Diacylglycerol
palmitoleoyl-oleoyl-glycerol (16:1/18:1) [1]*	Lipid	Diacylglycerol
palmitoleoylcarnitine (C16:1)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
palmitoleylcholine	Lipid	Fatty Acid Metabolism (Acyl Choline)
palmitoyl dihydro sphingomyelin (d18:0/16:0)*	Lipid	Sphingolipid Metabolism
palmitoyl sphingomyelin (d18:1/16:0)	Lipid	Sphingolipid Metabolism
palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2]*	Lipid	Diacylglycerol
palmitoyl-linoleoyl-glycerol (16:0/18:2) [1]*	Lipid	Diacylglycerol
palmitoyl-linoleoyl-glycerol (16:0/18:2) [2]*	Lipid	Diacylglycerol
palmitoyl-myristoyl-glycerol (16:0/14:0) [2]	Lipid	Diacylglycerol
palmitoyl-oleoyl-glycerol (16:0/18:1) [1]*	Lipid	Diacylglycerol
palmitoyl-oleoyl-glycerol (16:0/18:1) [2]*	Lipid	Diacylglycerol
palmitoyl-palmitoyl-glycerol (16:0/16:0) [1]*	Lipid	Diacylglycerol
palmitoyl-palmitoyl-glycerol (16:0/16:0) [2]*	Lipid	Diacylglycerol
palmitoylcarnitine (C16)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
palmitoylcholine	Lipid	Fatty Acid Metabolism (Acyl Choline)
pantothenate	Cofactors and Vitamins	Pantothenate and CoA Metabolism
paraxanthine	Xenobiotics	Xanthine Metabolism
perfluorooctanesulfonic acid (PFOS)	Xenobiotics	Chemical
phenol sulfate	Amino Acid	Tyrosine Metabolism
phenylacetylcarnitine	Peptide	Acetylated Peptides
phenylacetylglutamate	Peptide	Acetylated Peptides
phenylacetylglutamine	Peptide	Acetylated Peptides
phenylalanine	Amino Acid	Phenylalanine Metabolism
phenyllactate (PLA)	Amino Acid	Phenylalanine Metabolism
phenylpyruvate	Amino Acid	Phenylalanine Metabolism
phosphate	Energy	Oxidative Phosphorylation
phosphoethanolamine	Lipid	Phospholipid Metabolism
picolinate	Amino Acid	Tryptophan Metabolism
pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
pipicolate	Amino Acid	Lysine Metabolism
piperine	Xenobiotics	Food Component/Plant
pregn steroid monosulfate*	Lipid	Steroid
pregnenediol-3-glucuronide	Lipid	Steroid
pregnen-diol disulfate*	Lipid	Steroid
pregnenolone sulfate	Lipid	Steroid
pro-hydroxy-pro	Amino Acid	Urea cycle; Arginine and Proline Metabolism
proline	Amino Acid	Urea cycle; Arginine and Proline Metabolism
prolylglycine	Peptide	Dipeptide
propionylcarnitine (C3)	Lipid	Fatty Acid Metabolism (also BCAA Metabolism)
propionylglycine	Lipid	Fatty Acid Metabolism (also BCAA Metabolism)
propyl 4-hydroxybenzoate sulfate	Xenobiotics	Benzoate Metabolism

pseudouridine	Nucleotide	Pyrimidine Metabolism, Uracil containing
pyridoxate	Cofactors and Vitamins	Vitamin B6 Metabolism
pyroglutamine*	Amino Acid	Glutamate Metabolism
pyrraline	Xenobiotics	Food Component/Plant
pyruvate	Carbohydrate	Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
quininate	Xenobiotics	Food Component/Plant
quinine	Xenobiotics	Drug
quinolinate	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism
retinal	Xenobiotics	Food Component/Plant
retinol (Vitamin A)	Cofactors and Vitamins	Vitamin A Metabolism
ribitol	Carbohydrate	Pentose Metabolism
ribonate	Carbohydrate	Pentose Metabolism
S-1-pyrroline-5-carboxylate	Amino Acid	Glutamate Metabolism
S-allylcysteine	Xenobiotics	Food Component/Plant
S-methylcysteine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
S-methylcysteine sulfoxide	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
S-methylmethionine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
saccharin	Xenobiotics	Food Component/Plant
salicylate	Xenobiotics	Drug
salicyluric glucuronide*	Xenobiotics	Drug
sarcosine	Amino Acid	Glycine, Serine and Threonine Metabolism
serine	Amino Acid	Glycine, Serine and Threonine Metabolism
serotonin	Amino Acid	Tryptophan Metabolism
sphinganine	Lipid	Sphingolipid Metabolism
sphinganine-1-phosphate	Lipid	Sphingolipid Metabolism
sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d17:2/16:0, d18:2/15:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:0/18:0, d19:0/17:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:0/20:0, d16:0/22:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/14:0, d16:1/16:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0)	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/18:1, d18:2/18:0)	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/19:0, d19:1/18:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/20:0, d16:1/22:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/20:1, d18:2/20:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/20:2, d18:2/20:1, d16:1/22:2)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/22:2, d18:2/22:1, d16:1/24:2)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/24:1, d18:2/24:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:2/14:0, d18:1/14:1)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:2/16:0, d18:1/16:1)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:2/18:1)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:2/21:0, d16:2/23:0)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:2/23:1)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:2/24:1, d18:1/24:2)*	Lipid	Sphingolipid Metabolism
sphingomyelin (d18:2/24:2)*	Lipid	Sphingolipid Metabolism
sphingosine	Lipid	Sphingolipid Metabolism
sphingosine 1-phosphate	Lipid	Sphingolipid Metabolism
stachydrine	Xenobiotics	Food Component/Plant
stearate (18:0)	Lipid	Long Chain Fatty Acid
stearidonate (18:4n3)	Lipid	Polyunsaturated Fatty Acid (n3 and n6)
stearoyl ethanolamide	Lipid	Endocannabinoid
stearoyl sphingomyelin (d18:1/18:0)	Lipid	Sphingolipid Metabolism
stearoyl-arachidonoyl-glycerol (18:0/20:4) [1]*	Lipid	Diacylglycerol
stearoyl-arachidonoyl-glycerol (18:0/20:4) [2]*	Lipid	Diacylglycerol
stearoylcarnitine (C18)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
stearoylcholine*	Lipid	Fatty Acid Metabolism (Acyl Choline)
suberoylcarnitine (C8-DC)	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
succinate	Energy	TCA Cycle
succinimide	Xenobiotics	Chemical
succinylcarnitine (C4-DC)	Energy	TCA Cycle
sulfate*	Xenobiotics	Chemical
tartarate	Xenobiotics	Food Component/Plant
tartronate (hydroxymalonate)	Xenobiotics	Bacterial/Fungal
taurine	Amino Acid	Methionine, Cysteine, SAM and Taurine Metabolism
taurochenodeoxycholate	Lipid	Primary Bile Acid Metabolism
taurochenolate sulfate	Lipid	Secondary Bile Acid Metabolism
tauroolithocholate 3-sulfate	Lipid	Secondary Bile Acid Metabolism
theanine	Xenobiotics	Food Component/Plant
theobromine	Xenobiotics	Xanthine Metabolism
theophylline	Xenobiotics	Xanthine Metabolism
thioprolin	Xenobiotics	Chemical
threonate	Cofactors and Vitamins	Ascorbate and Aldarate Metabolism
threonine	Amino Acid	Glycine, Serine and Threonine Metabolism
thymol sulfate	Xenobiotics	Food Component/Plant
thyroxine	Amino Acid	Tyrosine Metabolism
tiglylcarnitine (C5:1-DC)	Amino Acid	Leucine, Isoleucine and Valine Metabolism
trans-4-hydroxyproline	Amino Acid	Urea cycle; Arginine and Proline Metabolism
trans-urocanate	Amino Acid	Histidine Metabolism

tricosanoyl sphingomyelin (d18:1/23:0)*	Lipid	Sphingolipid Metabolism
trigonelline (N'-methylnicotinate)	Cofactors and Vitamins	Nicotinate and Nicotinamide Metabolism
trimethylamine N-oxide	Lipid	Phospholipid Metabolism
tryptophan	Amino Acid	Tryptophan Metabolism
tryptophan betaine	Amino Acid	Tryptophan Metabolism
tyramine O-sulfate	Amino Acid	Tyrosine Metabolism
tyrosine	Amino Acid	Tyrosine Metabolism
umbelliferone sulfate	Xenobiotics	Food Component/Plant
uracil	Nucleotide	Pyrimidine Metabolism, Uracil containing
urate	Nucleotide	Purine Metabolism, (Hypo)Xanthine/Inosine containing
urea	Amino Acid	Urea cycle; Arginine and Proline Metabolism
uridine	Nucleotide	Pyrimidine Metabolism, Uracil containing
ursodeoxycholate	Lipid	Secondary Bile Acid Metabolism
valine	Amino Acid	Leucine, Isoleucine and Valine Metabolism
vanillactate	Amino Acid	Tyrosine Metabolism
vanillylmandelate (VMA)	Amino Acid	Tyrosine Metabolism
xanthine	Nucleotide	Purine Metabolism, (Hypo)Xanthine/Inosine containing
xanthurenate	Amino Acid	Tryptophan Metabolism
ximenoylcarnitine (C26:1)*	Lipid	Fatty Acid Metabolism(Acyl Carnitine)
xylose	Carbohydrate	Pentose Metabolism



Supplemental Figure 1. Principal component analysis (PCA) for the metabolomic data for all volunteers and treatments, for both time-points (A; $n=32 \times 4$ treatments $\times 2$ time-points (day 1, day 29)), and for the ratio of post- to pre-treatment (B; $n=32 \times 4$ treatments).

Scores on the third and fourth principal components are shown and the percentage variance accounted for by each component indicated on each axis. The circle represents the low dose monomeric flavonols treatment, the square the high dose monomeric flavanols, the triangle the placebo, and the star the oligomeric procyanidins. For (A), open symbols represent day 1 and closed symbols day 29 of the treatments. Six individuals are highlighted; the volunteer number is given and an ellipse shows the spread of scores for each of these volunteers.